PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
1528066-0	1992	Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2"-deoxycoformycin.	Pentostatin	77-95	CD4 molecule	Homo sapiens	26-29
1528066-1	1992	The leukemic cells of a patient with CD4+ prolymphocytic leukemia were treated in vitro with 5 microM deoxyadenosine and 60 microM 2"-deoxycoformycin (dCF), an inhibitor of adenosine deaminase (ADA).	Pentostatin	131-149	CD4 molecule	Homo sapiens	37-40
1528066-1	1992	The leukemic cells of a patient with CD4+ prolymphocytic leukemia were treated in vitro with 5 microM deoxyadenosine and 60 microM 2"-deoxycoformycin (dCF), an inhibitor of adenosine deaminase (ADA).	Pentostatin	131-149	adenosine deaminase	Homo sapiens	173-192
1504408-0	1992	Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia.	Pentostatin	0-11	adenosine deaminase	Homo sapiens	16-35
1504408-11	1992	CONCLUSIONS: Pentostatin is a purine analog that inhibits adenosine deaminase, a key enzyme necessary for purine salvage.	Pentostatin	13-24	adenosine deaminase	Homo sapiens	58-77
1628382-3	1992	A significant increase of basal DCF fluorescence was induced by stimuli namely thrombin, arachidonic acid, the Ca2+ ionophore A23187 and PMA.	Pentostatin	32-35	coagulation factor II, thrombin	Homo sapiens	79-87
1632801-6	1992	Kinetic constants for the association and dissociation of coformycin and 2"-deoxycoformycin with the bovine brain adenosine deaminase are reported.	Pentostatin	73-91	adenosine deaminase	Bos taurus	114-133
1346578-3	1992	One patient with a CD19+/CD5+/CD25- phenotype and one with a pentostatin-treated CD19+/CD25- variant form had minor responses.	Pentostatin	61-72	CD19 molecule	Homo sapiens	81-85
1346578-3	1992	One patient with a CD19+/CD5+/CD25- phenotype and one with a pentostatin-treated CD19+/CD25- variant form had minor responses.	Pentostatin	61-72	interleukin 2 receptor subunit alpha	Homo sapiens	87-91
1611498-6	1992	Similar protection against focal ischemic brain damage was evident when the adenosine deaminase inhibitor, deoxycoformycin (500 micrograms/kg), was administered prior to the onset of ischemia.	Pentostatin	107-122	adenosine deaminase	Rattus norvegicus	76-95
1948767-1	1991	The developmental toxicity of the potent adenosine deaminase (ADA) inhibitor, pentostatin (2"-deoxycoformycin), was investigated in pregnant rats and rabbits administered daily iv doses during organogenesis.	Pentostatin	78-89	adenosine deaminase	Rattus norvegicus	41-60
1318679-6	1992	Rats pretreated with the adenosine deaminase inhibitor deoxycoformycin excreted more ara-MAP and much less ara-H and allantoin.	Pentostatin	55-70	adenosine deaminase	Rattus norvegicus	25-44
1729390-0	1992	Rat brain adenosine deaminase after 2"-deoxycoformycin administration: biochemical properties and evidence for reduced enzyme levels detected by 2"-[3H]deoxycoformycin ligand binding.	Pentostatin	36-54	adenosine deaminase	Rattus norvegicus	10-29
1729390-1	1992	Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF.	Pentostatin	113-131	adenosine deaminase	Rattus norvegicus	31-50
1729390-1	1992	Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF.	Pentostatin	113-131	adenosine deaminase	Rattus norvegicus	52-55
1729390-1	1992	Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF.	Pentostatin	113-131	adenosine deaminase	Rattus norvegicus	99-102
1729390-1	1992	Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF.	Pentostatin	133-136	adenosine deaminase	Rattus norvegicus	31-50
1729390-1	1992	Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF.	Pentostatin	133-136	adenosine deaminase	Rattus norvegicus	52-55
1729390-1	1992	Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF.	Pentostatin	133-136	adenosine deaminase	Rattus norvegicus	99-102
1729390-1	1992	Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF.	Pentostatin	287-290	adenosine deaminase	Rattus norvegicus	31-50
1729390-1	1992	Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF.	Pentostatin	287-290	adenosine deaminase	Rattus norvegicus	52-55
1729390-1	1992	Near total inhibition of brain adenosine deaminase (ADA) activity in rats injected with the potent ADA inhibitor 2"-deoxycoformycin (DCF) was previously shown to reduce enzyme activity for up to 50 days during which time the enzyme exhibited reduced sensitivity to in vivo inhibition by DCF.	Pentostatin	287-290	adenosine deaminase	Rattus norvegicus	99-102
1729390-2	1992	Here, we investigated the biochemical properties of ADA and the basis for its reduced activity after DCF treatment.	Pentostatin	101-104	adenosine deaminase	Rattus norvegicus	52-55
1729390-3	1992	It was found that much higher doses of DCF were required to inhibit ADA in DCF-treated compared with drug-naive animals.	Pentostatin	39-42	adenosine deaminase	Rattus norvegicus	68-71
1729390-3	1992	It was found that much higher doses of DCF were required to inhibit ADA in DCF-treated compared with drug-naive animals.	Pentostatin	75-78	adenosine deaminase	Rattus norvegicus	68-71
1729390-4	1992	Fourteen days after DCF administration, reduced ADA activity in brain homogenates was due to a decrease in Vmax, rather than to an altered Km of ADA for adenosine.	Pentostatin	20-23	adenosine deaminase	Rattus norvegicus	48-51
1729390-6	1992	The IC50 value for DCF inhibition of ADA in hypothalamus was unchanged.	Pentostatin	19-22	adenosine deaminase	Rattus norvegicus	37-40
1729390-7	1992	However, the Ki for DCF inhibition of ADA in whole brain increased by fivefold.	Pentostatin	20-23	adenosine deaminase	Rattus norvegicus	38-41
1729390-8	1992	Sucrose gradient analysis of brain ADA revealed only one corresponding peak of activity and [3H]DCF-labeled ADA in DCF-treated and control rats.	Pentostatin	96-99	adenosine deaminase	Rattus norvegicus	35-38
1729390-8	1992	Sucrose gradient analysis of brain ADA revealed only one corresponding peak of activity and [3H]DCF-labeled ADA in DCF-treated and control rats.	Pentostatin	96-99	adenosine deaminase	Rattus norvegicus	108-111
1729390-8	1992	Sucrose gradient analysis of brain ADA revealed only one corresponding peak of activity and [3H]DCF-labeled ADA in DCF-treated and control rats.	Pentostatin	115-118	adenosine deaminase	Rattus norvegicus	35-38
1729390-8	1992	Sucrose gradient analysis of brain ADA revealed only one corresponding peak of activity and [3H]DCF-labeled ADA in DCF-treated and control rats.	Pentostatin	115-118	adenosine deaminase	Rattus norvegicus	108-111
1729390-9	1992	A radioligand filtration assay with [3H]DCF was developed to assess the effects of DCF on ADA protein levels.	Pentostatin	40-43	adenosine deaminase	Rattus norvegicus	90-93
1730260-3	1992	Subsequently, infected T cells were selected on the basis of their ADA expression, by exposure to a combination of the toxic agent xylofuranosyl-adenine and the specific ADA inhibitor 2"-deoxycoformycin.	Pentostatin	184-202	adenosine deaminase	Homo sapiens	170-173
1731400-1	1992	The viability of early mouse embryos is acutely sensitive to (R)-deoxycoformycin (pentostatin), a tight-binding inhibitor of adenosine deaminase (ADA).	Pentostatin	61-80	adenosine deaminase	Mus musculus	125-144
1731400-1	1992	The viability of early mouse embryos is acutely sensitive to (R)-deoxycoformycin (pentostatin), a tight-binding inhibitor of adenosine deaminase (ADA).	Pentostatin	61-80	adenosine deaminase	Mus musculus	146-149
1731400-1	1992	The viability of early mouse embryos is acutely sensitive to (R)-deoxycoformycin (pentostatin), a tight-binding inhibitor of adenosine deaminase (ADA).	Pentostatin	82-93	adenosine deaminase	Mus musculus	125-144
1731400-1	1992	The viability of early mouse embryos is acutely sensitive to (R)-deoxycoformycin (pentostatin), a tight-binding inhibitor of adenosine deaminase (ADA).	Pentostatin	82-93	adenosine deaminase	Mus musculus	146-149
1441846-5	1992	The enzyme was inhibited by erythro-9-(2-hydroxy-3-nonyl)adenine and 2"-deoxycoformycin with Ki 4.4 x 10(-7) M and 3.2 x 10(-7) M for mitochondrial ADA and 4.9 x 10(-7) M 2.8 x 10(-7) M for cytosolic ADA.	Pentostatin	69-87	adenosine deaminase	Rattus norvegicus	148-151
1441846-5	1992	The enzyme was inhibited by erythro-9-(2-hydroxy-3-nonyl)adenine and 2"-deoxycoformycin with Ki 4.4 x 10(-7) M and 3.2 x 10(-7) M for mitochondrial ADA and 4.9 x 10(-7) M 2.8 x 10(-7) M for cytosolic ADA.	Pentostatin	69-87	adenosine deaminase	Rattus norvegicus	200-203
1948767-1	1991	The developmental toxicity of the potent adenosine deaminase (ADA) inhibitor, pentostatin (2"-deoxycoformycin), was investigated in pregnant rats and rabbits administered daily iv doses during organogenesis.	Pentostatin	78-89	adenosine deaminase	Rattus norvegicus	62-65
1948767-1	1991	The developmental toxicity of the potent adenosine deaminase (ADA) inhibitor, pentostatin (2"-deoxycoformycin), was investigated in pregnant rats and rabbits administered daily iv doses during organogenesis.	Pentostatin	91-109	adenosine deaminase	Rattus norvegicus	62-65
2033586-9	1991	In the presence of the potent ADA inhibitor 2"-deoxycoformycin, 6-halo-substituted ddPs failed to exert an in vitro antiretroviral effect.	Pentostatin	44-62	adenosine deaminase	Homo sapiens	30-33
1877368-4	1991	Inhibition of adenosine deaminase by deoxycoformycin produced a significant 1.4-fold increase in extracellular adenosine levels and a fall in inosine and hypoxanthine.	Pentostatin	37-52	adenosine deaminase	Rattus norvegicus	14-33
1715181-4	1991	Deoxycoformycin (10(-4) M), an inhibitor of adenosine deaminase activity, prevented the increase in superoxide production associated with adenosine deaminase addition.	Pentostatin	0-15	adenosine deaminase	Homo sapiens	44-63
1715181-4	1991	Deoxycoformycin (10(-4) M), an inhibitor of adenosine deaminase activity, prevented the increase in superoxide production associated with adenosine deaminase addition.	Pentostatin	0-15	adenosine deaminase	Homo sapiens	138-157
2033591-7	1991	The anti-HIV activity of 1f and 1i was abolished when the ADA inhibitor, 2"-deoxycoformycin, was added to the test mixture.	Pentostatin	73-91	adenosine deaminase	Homo sapiens	58-61
1826794-2	1991	To clarify the process whereby thymocytes are destroyed in the absence of adenosine deaminase activity, we induced a parallel condition in mice through the injection of an inhibitor of adenosine deaminase, deoxycoformycin.	Pentostatin	206-221	adenosine deaminase	Mus musculus	185-204
1995064-5	1991	In medium supplemented with the adenosine deaminase inhibitor deoxycoformycin, the T cells with increased 5"-nucleotidase accumulated less nucleotides from exogenously added deoxyadenosine, or 9-beta-D-arabinofuranosyladenine, than did parental T lymphocytes.	Pentostatin	62-77	adenosine deaminase	Homo sapiens	32-51
1671090-0	1991	Brain adenosine and transmitter amino acid release from the ischemic rat cerebral cortex: effects of the adenosine deaminase inhibitor deoxycoformycin.	Pentostatin	135-150	adenosine deaminase	Rattus norvegicus	105-124
1671090-1	1991	The effects of a potent adenosine deaminase inhibitor, deoxycoformycin, on purine and amino acid neuro-transmitter release from the ischemic rat cerebral cortex were studied with the cortical cup technique.	Pentostatin	55-70	adenosine deaminase	Rattus norvegicus	24-43
1995064-5	1991	In medium supplemented with the adenosine deaminase inhibitor deoxycoformycin, the T cells with increased 5"-nucleotidase accumulated less nucleotides from exogenously added deoxyadenosine, or 9-beta-D-arabinofuranosyladenine, than did parental T lymphocytes.	Pentostatin	62-77	5'-nucleotidase ecto	Homo sapiens	106-121
1995064-7	1991	The T cells with elevated 5"-nucleotidase activity formed more 2",3"-dideoxyadenosine than did parental cells, in deoxycoformycin-supplemented medium.	Pentostatin	114-129	5'-nucleotidase ecto	Homo sapiens	26-41
1679757-2	1991	Three new purine nucleoside analogues, deoxycoformycin, fludarabine, and 2-chlorodeoxyadenosine, affect the normal function of the purine salvage pathway by inhibiting ADA or by acting as analogs of the ADA substrates.	Pentostatin	39-54	adenosine deaminase	Homo sapiens	168-171
1679757-2	1991	Three new purine nucleoside analogues, deoxycoformycin, fludarabine, and 2-chlorodeoxyadenosine, affect the normal function of the purine salvage pathway by inhibiting ADA or by acting as analogs of the ADA substrates.	Pentostatin	39-54	adenosine deaminase	Homo sapiens	203-206
2165099-3	1990	The fluorochrome 2",7"-dichlorodihydrofluorescein (DCFH) (the nonfluorescent, reduced form of 2",7"-dichlorofluorescein (DCF] has been covalently linked to bovine serum albumin (BSA), which can be used to form an immune complex with anti-BSA immunoglobulin.	Pentostatin	51-54	albumin	Homo sapiens	163-176
1761363-0	1991	Host resistance to murine malaria in mice exposed to the adenosine deaminase inhibitor, 2"-deoxycoformycin.	Pentostatin	88-106	adenosine deaminase	Mus musculus	57-76
1761363-2	1991	The purpose this study was to profile host resistance to infection with this organism in mice exposed to 2"-deoxycoformycin (2dCF), a potent adenosine deaminase (ADA) inhibitor.	Pentostatin	105-123	adenosine deaminase	Mus musculus	141-160
1761363-2	1991	The purpose this study was to profile host resistance to infection with this organism in mice exposed to 2"-deoxycoformycin (2dCF), a potent adenosine deaminase (ADA) inhibitor.	Pentostatin	105-123	adenosine deaminase	Mus musculus	162-165
1761363-2	1991	The purpose this study was to profile host resistance to infection with this organism in mice exposed to 2"-deoxycoformycin (2dCF), a potent adenosine deaminase (ADA) inhibitor.	Pentostatin	125-129	adenosine deaminase	Mus musculus	141-160
1761363-2	1991	The purpose this study was to profile host resistance to infection with this organism in mice exposed to 2"-deoxycoformycin (2dCF), a potent adenosine deaminase (ADA) inhibitor.	Pentostatin	125-129	adenosine deaminase	Mus musculus	162-165
1761363-3	1991	Inhibition of ADA activity by 2dFC results in defective T-cell function and either suppression or augmentation of the humoral response, depending on whether 2dCF exposure precedes (suppression) or follows (augmentation) immunization.	Pentostatin	157-161	adenosine deaminase	Mus musculus	14-17
2262486-7	1990	Future studies will (1) determine the optimal dose and schedule of cytosine arabinoside needed to exploit the increased Ara-CTP accumulation in T-cell blasts, (2) determine the efficacy of a new agent, deoxycoformycin, an inhibitor of adenosine deaminase, to exploit the biochemical phenotype of T-cell blasts, and (3) assess the ability of conjugated anti-T monoclonal antibodies to deliver a cytotoxic agent, thus exploiting unique antigenic determinants at the cell surface.	Pentostatin	202-217	adenosine deaminase	Homo sapiens	235-254
2273300-0	1990	Combined effects of interferon and 2"-deoxycoformycin on 2",5"-oligoadenylate synthetase and adenosine deaminase in hairy cell and chronic lymphocytic leukemia cells.	Pentostatin	35-53	adenosine deaminase	Homo sapiens	93-112
2273300-1	1990	The combined effects of interferon (IFN) and 2"-deoxycoformycin (DCF) on 2",5"-oligoadenylate (2-5A) synthetase and adenosine deaminase (ADA) activity were examined in vitro in peripheral blood mononuclear cells from patients with hairy cell leukemia (HCL) and chronic lymphocytic leukemia (CLL).	Pentostatin	65-68	adenosine deaminase	Homo sapiens	137-140
2273300-2	1990	In HCL cells, the effects of IFN and DCF on both OAS and ADA activity were strictly antagonistic.	Pentostatin	37-40	adenosine deaminase	Homo sapiens	57-60
2273300-4	1990	If OAS and ADA are important in the antitumor effects of IFN and DCF, our results suggest that combination therapy with IFN and DCF could be counterproductive.	Pentostatin	65-68	adenosine deaminase	Homo sapiens	11-14
2273300-4	1990	If OAS and ADA are important in the antitumor effects of IFN and DCF, our results suggest that combination therapy with IFN and DCF could be counterproductive.	Pentostatin	65-68	interferon alpha 1	Homo sapiens	120-123
2273300-4	1990	If OAS and ADA are important in the antitumor effects of IFN and DCF, our results suggest that combination therapy with IFN and DCF could be counterproductive.	Pentostatin	128-131	interferon alpha 1	Homo sapiens	57-60
2399991-2	1990	In the presence of the adenosine deaminase inhibitor deoxycoformycin uptake of [3H]adenosine into brush-border membrane vesicles is stimulated fivefold by an inwardly directed Na gradient.	Pentostatin	53-68	adenosine deaminase	Oryctolagus cuniculus	23-42
2275794-0	1990	Structural and conformational analysis of pentostatin (2"-deoxycoformycin), a potent inhibitor of adenosine deaminase.	Pentostatin	42-53	adenosine deaminase	Homo sapiens	98-117
2275794-0	1990	Structural and conformational analysis of pentostatin (2"-deoxycoformycin), a potent inhibitor of adenosine deaminase.	Pentostatin	55-73	adenosine deaminase	Homo sapiens	98-117
2275794-1	1990	X-ray, NMR and molecular mechanics studies on pentostatin (C11H16N4O4), a potent inhibitor of the enzyme adenosine deaminase, have been carried out to study the structure and conformation.	Pentostatin	46-57	adenosine deaminase	Homo sapiens	105-124
1898656-4	1991	A similar accumulation was observed with both unstimulated and stimulated PMNs after the addition of deoxycoformycin (dCF, 1-100 microM), an inhibitor of adenosine deaminase.	Pentostatin	101-116	adenosine deaminase	Homo sapiens	154-173
1898656-4	1991	A similar accumulation was observed with both unstimulated and stimulated PMNs after the addition of deoxycoformycin (dCF, 1-100 microM), an inhibitor of adenosine deaminase.	Pentostatin	118-121	adenosine deaminase	Homo sapiens	154-173
2172653-9	1990	Two inhibitors of xanthine oxidase, allopurinol and oxypurinol, were also protective as was deoxycoformycin, an inhibitor of adenosine deaminase.	Pentostatin	92-107	adenosine deaminase	Rattus norvegicus	125-144
2357554-1	1990	The use of a relatively specific adenosine deaminase inhibitor, 2"-deoxycoformycin (1.0 microM), has revealed an active transport of adenosine into astrocytes in primary cultures.	Pentostatin	64-82	adenosine deaminase	Homo sapiens	33-52
2139230-5	1990	Cultures containing 10(-7) M 2"-deoxycoformycin retained approximately 10% of residual ADA activity of control cultures.	Pentostatin	29-47	adenosine deaminase	Mus musculus	87-90
2190792-5	1990	The antimetabolites consist of methotrexate, the pyrimidine and purine analogues, and pentostatin, an adenosine deaminase inhibitor and relative newcomer to the class.	Pentostatin	86-97	adenosine deaminase	Homo sapiens	102-121
2316512-4	1990	Furthermore, DCF and agents that differentiated HL-60 cells had opposing effects on adenosine deaminase and 2",5"-oligoadenylate synthetase activity.	Pentostatin	13-16	adenosine deaminase	Homo sapiens	84-103
2179470-0	1990	2"-Deoxycoformycin inhibition of adenosine deaminase in rat brain: in vivo and in vitro analysis of specificity, potency, and enzyme recovery.	Pentostatin	0-18	adenosine deaminase	Rattus norvegicus	33-52
2179470-1	1990	2"-Deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), is increasingly used as a tool to investigate adenosine metabolism and neuromodulation.	Pentostatin	0-18	adenosine deaminase	Rattus norvegicus	48-67
2179470-1	1990	2"-Deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), is increasingly used as a tool to investigate adenosine metabolism and neuromodulation.	Pentostatin	0-18	adenosine deaminase	Rattus norvegicus	69-72
2179470-1	1990	2"-Deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), is increasingly used as a tool to investigate adenosine metabolism and neuromodulation.	Pentostatin	20-23	adenosine deaminase	Rattus norvegicus	48-67
2179470-1	1990	2"-Deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), is increasingly used as a tool to investigate adenosine metabolism and neuromodulation.	Pentostatin	20-23	adenosine deaminase	Rattus norvegicus	69-72
2179470-4	1990	In vivo, DCF inhibited ADA with ED50 values ranging from 155 to 280 micrograms/kg at 2 h posttreatment, and 98% inhibition was achieved with 1 mg/kg.	Pentostatin	9-12	adenosine deaminase	Rattus norvegicus	23-26
2179470-10	1990	The very low doses of DCF required for ADA inhibition in vivo are consistent with the high potency of this drug against ADA in vitro, and any physiological effects observed at low doses might therefore be ascribed to inhibition of ADA.	Pentostatin	22-25	adenosine deaminase	Rattus norvegicus	39-42
2179470-10	1990	The very low doses of DCF required for ADA inhibition in vivo are consistent with the high potency of this drug against ADA in vitro, and any physiological effects observed at low doses might therefore be ascribed to inhibition of ADA.	Pentostatin	22-25	adenosine deaminase	Rattus norvegicus	120-123
2179470-10	1990	The very low doses of DCF required for ADA inhibition in vivo are consistent with the high potency of this drug against ADA in vitro, and any physiological effects observed at low doses might therefore be ascribed to inhibition of ADA.	Pentostatin	22-25	adenosine deaminase	Rattus norvegicus	120-123
2308364-3	1990	Myocardial adenosine levels were augmented during ischemia by providing exogenous adenosine in the cardioplegic solution or by inhibiting adenosine degradation with 2-deoxycoformycin, a noncompetitive inhibitor of adenosine deaminase.	Pentostatin	165-182	adenosine deaminase	Oryctolagus cuniculus	214-233
2291566-9	1990	We are using immortalized stromal cell lines resistant to deoxycoformycin (dCF) to select transduced murine HSC containing human ADA in vitro.	Pentostatin	75-78	adenosine deaminase	Homo sapiens	129-132
2303314-3	1990	Recently, we and others have demonstrated that in cells rendered ADA deficient by treatment with deoxycoformycin, dAdo affects T-cell activation events which precede DNA synthesis, such as interleukin 2 receptor (IL-2R) expression and IL-2 production.	Pentostatin	97-112	interleukin 2 receptor subunit alpha	Homo sapiens	189-211
2303314-3	1990	Recently, we and others have demonstrated that in cells rendered ADA deficient by treatment with deoxycoformycin, dAdo affects T-cell activation events which precede DNA synthesis, such as interleukin 2 receptor (IL-2R) expression and IL-2 production.	Pentostatin	97-112	interleukin 2 receptor subunit alpha	Homo sapiens	213-218
2303314-3	1990	Recently, we and others have demonstrated that in cells rendered ADA deficient by treatment with deoxycoformycin, dAdo affects T-cell activation events which precede DNA synthesis, such as interleukin 2 receptor (IL-2R) expression and IL-2 production.	Pentostatin	97-112	interleukin 2	Homo sapiens	213-217
35183655-6	2022	Finally, we show that addition of angiotensinogen (2nM) to the ARPE-19 cells increased oxidative stress as assessed by DCF fluorescence that was blocked by pretreatment of the cells with either the NADPH oxidase 1/4 inhibitor GKT137831, apocynin or atorvastatin, but not the AT1 receptor antagonist losartan.	Pentostatin	119-122	angiotensinogen	Homo sapiens	34-49
34563676-0	2022	Epitranscriptomics modifier Pentostatin indirectly triggers Toll-like Receptor 3 and can enhance immune infiltration in tumours.	Pentostatin	28-39	toll-like receptor 3	Mus musculus	60-80
34563676-4	2022	Accordingly, we demonstrated in mice that the anticancer activity of Pentostatin required Toll-like Receptor 3, the type I interferon receptor and T-cells.	Pentostatin	69-80	toll-like receptor 3	Mus musculus	90-110
34227372-14	2021	The limits of detection (LODs, S/N>=3) and limits of quantification (LOQs, S/N>=10) of the 2"-amino-2"-deoxyadenosine and pentostatin in the fermentation broth were 0.003-0.060 mug/L and 0.010-0.200 mug/L, respectively.	Pentostatin	122-133	TARBP2 subunit of RISC loading complex	Homo sapiens	69-73
27463984-11	1990	A group of 12 patients who had received alpha-IFN immediately prior to treatment with DCF and had obtained clinical and haematological benefit had fewer infections with DCF than the group who had either not received IFN immediately before or who had failed to respond to it.	Pentostatin	86-89	interferon alpha 1	Homo sapiens	46-49
27463984-11	1990	A group of 12 patients who had received alpha-IFN immediately prior to treatment with DCF and had obtained clinical and haematological benefit had fewer infections with DCF than the group who had either not received IFN immediately before or who had failed to respond to it.	Pentostatin	169-172	interferon alpha 1	Homo sapiens	46-49
33764753-4	2021	During the formation of a co-gel with RhB (or DCF) and DAE, the chirality of FLG could be effectively transferred to both the fluorescent and photochromic components, which induced them with chiroptical properties including CPL and circular dichroism (CD).	Pentostatin	46-49	filaggrin	Homo sapiens	77-80
35432485-11	2022	ACP with high CXCL6 showed remarkable drug sensitivity to Pentostatin and Wortmannin via CellMiner database analysis.	Pentostatin	58-69	C-X-C motif chemokine ligand 6	Homo sapiens	14-19
2497184-7	1989	Analysis of 2"-deoxyadenosine-challenged cells showed that TJF-2 cells accumulated significant levels of deoxyadenosine triphosphate, whereas normal T cells did not unless they were also incubated with the ADA inhibitor deoxycoformycin.	Pentostatin	220-235	adenosine deaminase	Homo sapiens	206-209
2572681-6	1989	Deoxycoformycin, an inhibitor of adenosine deaminase, failed to alter the levels of cyclic AMP or tyrosine hydroxylase activity.	Pentostatin	0-15	adenosine deaminase	Rattus norvegicus	33-52
2623648-0	1989	Early postimplantation embryolethality in mice following in utero inhibition of adenosine deaminase with 2"-deoxycoformycin.	Pentostatin	105-123	adenosine deaminase	Mus musculus	80-99
2623648-4	1989	In the present study, we examined the effects of intrauterine exposure to 2"-deoxycoformycin (dCF; pentostatin), a potent irreversible inhibitor of ADA, on early postimplantation development.	Pentostatin	74-92	adenosine deaminase	Mus musculus	148-151
2623648-4	1989	In the present study, we examined the effects of intrauterine exposure to 2"-deoxycoformycin (dCF; pentostatin), a potent irreversible inhibitor of ADA, on early postimplantation development.	Pentostatin	94-97	adenosine deaminase	Mus musculus	148-151
2623648-9	1989	Treatment of pregnant dams with dCF on day 7 produced a complete (greater than 99%) inhibition of ADA activity in the antimesometrial decidua by 30 min, induced excessive cell death in the prospective neural plate and primary mesenchyme of the trilaminar disc by 6 h, and arrested embryonic development at an early somite stage.	Pentostatin	32-35	adenosine deaminase	Mus musculus	98-101
2789273-3	1989	In this phase II study of the Leukemia Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC), the efficacy and toxicity of DCF were investigated in patients who were resistant to IFN-a treatment.	Pentostatin	161-164	interferon alpha 1	Homo sapiens	217-222
2789273-16	1989	Thus, DCF is highly active in patients with HCL resistant to IFN-a.	Pentostatin	6-9	interferon alpha 1	Homo sapiens	61-66
2790329-2	1989	In the presence of deoxyadenosine (dAdo), dCf inhibits T cell function as measured by DNA synthesis induced by stimuli in the rank order of mixed lymphocyte culture greater than murine monoclonal antibody OKT3 greater than phytohemagglutinin.	Pentostatin	42-45	ado	Drosophila melanogaster	35-39
2788175-7	1989	NH3 production derived only from the deamination of adenosine by the enzyme adenosine deaminase and was abolished by 0.4 microM 2"-deoxycoformycin, a specific inhibitor of adenosine deaminase.	Pentostatin	128-146	adenosine deaminase	Homo sapiens	172-191
2812252-4	1989	A relatively specific adenosine deaminase inhibitor, 2"-deoxycoformycin, was used in the present study.	Pentostatin	53-71	adenosine deaminase	Homo sapiens	22-41
2583256-2	1989	Anecdotal reports have suggested that patients who failed IFN could achieve durable responses with dCF, although the frequency with which this was said to have occurred was unknown.	Pentostatin	99-102	interferon alpha 1	Homo sapiens	58-61
2583256-3	1989	We reviewed the available data on the responsiveness of HCL to dCF after IFN therapy by analyzing cases reported in the literature and those treated under the Special Exception mechanism of the National Cancer Institute, Division of Cancer Treatment.	Pentostatin	63-66	interferon alpha 1	Homo sapiens	73-76
2583256-6	1989	dCF is an active agent in HCL both as initial therapy and for the salvage of patients who have failed IFN.	Pentostatin	0-3	interferon alpha 1	Homo sapiens	102-105
2502523-4	1989	DCF potentiated the antiproliferative activity of Ara-A not only in T-cell lines with high adenosine deaminase (ADA) activity, but also in some other cell lines with low ADA activity.	Pentostatin	0-3	adenosine deaminase	Homo sapiens	91-110
2502523-4	1989	DCF potentiated the antiproliferative activity of Ara-A not only in T-cell lines with high adenosine deaminase (ADA) activity, but also in some other cell lines with low ADA activity.	Pentostatin	0-3	adenosine deaminase	Homo sapiens	112-115
2502523-4	1989	DCF potentiated the antiproliferative activity of Ara-A not only in T-cell lines with high adenosine deaminase (ADA) activity, but also in some other cell lines with low ADA activity.	Pentostatin	0-3	adenosine deaminase	Homo sapiens	170-173
2783731-1	1989	2"-Deoxycoformycin (pentostatin [dCF]), a potent inhibitor of adenosine deaminase (ADA), was administered in a biweekly low-dose (2 to 4 mg/m2) intravenous (IV) schedule to patients with advanced hairy cell leukemia.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	62-81
2749584-6	1989	Similar potentiated forskolin effect (IC50, 0.53 microM) is seen if the ADA-treated human PRP is replenished with a low level of Ado (50 nM) after ADA inactivation by dCF and Ado-uptake blockade by dilazep.	Pentostatin	167-170	proline rich protein 2-like 1	Rattus norvegicus	90-93
2783731-1	1989	2"-Deoxycoformycin (pentostatin [dCF]), a potent inhibitor of adenosine deaminase (ADA), was administered in a biweekly low-dose (2 to 4 mg/m2) intravenous (IV) schedule to patients with advanced hairy cell leukemia.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	83-86
2783731-1	1989	2"-Deoxycoformycin (pentostatin [dCF]), a potent inhibitor of adenosine deaminase (ADA), was administered in a biweekly low-dose (2 to 4 mg/m2) intravenous (IV) schedule to patients with advanced hairy cell leukemia.	Pentostatin	20-31	adenosine deaminase	Homo sapiens	62-81
2783731-1	1989	2"-Deoxycoformycin (pentostatin [dCF]), a potent inhibitor of adenosine deaminase (ADA), was administered in a biweekly low-dose (2 to 4 mg/m2) intravenous (IV) schedule to patients with advanced hairy cell leukemia.	Pentostatin	20-31	adenosine deaminase	Homo sapiens	83-86
3263401-1	1988	2"-Deoxycoformycin, a potent inhibitor of adenosine deaminase, was administered to three patients with cutaneous T cell lymphoma refractory to multiple treatment modalities.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	42-61
3263396-4	1988	Inhibition of adenosine deaminase by 80% with the tight-binding inhibitor 2"-deoxycoformycin led to a 20% increase in the residual adenine nucleotide pool.	Pentostatin	74-92	adenosine deaminase	Rattus norvegicus	14-33
2575348-2	1989	We now show that human monocytes are also highly sensitive in vitro to nanomolar concentrations of deoxyadenosine plus the ADA inhibitor deoxycoformycin, and to the ADA-resistant analogue 2-chlorodeoxyadenosine (CdA).	Pentostatin	137-152	adenosine deaminase	Homo sapiens	123-126
3262116-1	1988	The effects of the adenosine deaminase inhibitor, deoxycoformycin, on purine release from the rat cerebral cortex were studied with the cortical cup technique.	Pentostatin	50-65	adenosine deaminase	Rattus norvegicus	19-38
3260524-6	1988	These effects of ADA depended on its enzymatic activity as they could be blocked by preincubation with DCF.	Pentostatin	103-106	adenosine deaminase	Homo sapiens	17-20
2841534-7	1988	Special emphasis will be put on the clinical use of an ADA-inhibitor, deoxycoformycin.	Pentostatin	70-85	adenosine deaminase	Homo sapiens	55-58
2836002-2	1988	Adenosine deaminase activity of 6C3HED cells was ablated by incubation with 10(-6) mol/L deoxycoformycin (dCF).	Pentostatin	89-104	adenosine deaminase	Mus musculus	0-19
2836002-2	1988	Adenosine deaminase activity of 6C3HED cells was ablated by incubation with 10(-6) mol/L deoxycoformycin (dCF).	Pentostatin	106-109	adenosine deaminase	Mus musculus	0-19
3342099-4	1988	If ADA activity was blocked by 2"-deoxycoformycin (dCF, 5 microM), a tight-binding inhibitor of ADA, most of the Ado (96%) was incorporated into adenine nucleotides, whereas if Ado kinase activity was blocked with 5-iodotubercidin (10 microM), Ado was mainly (95%) metabolized into hypoxanthine.	Pentostatin	31-49	adenosine deaminase	Homo sapiens	3-6
3258602-2	1988	However, these dideoxynucleosides may be catabolized by human T cells, even when adenosine deaminase is inhibited by deoxycoformycin.	Pentostatin	117-132	adenosine deaminase	Homo sapiens	81-100
2842492-18	1988	Adenosine deaminase (10 micrograms/ml) caused some potentiation of EJPs; this action was prevented by a concentration (10 mumol/l) of deoxycoformycin, which had no effect of its own.	Pentostatin	134-149	adenosine deaminase	Oryctolagus cuniculus	0-19
3257147-0	1988	Opposite effects of recombinant interferon-alpha A and deoxycoformycin on adenosine deaminase activity in the Daudi B lymphoblastoid cell line.	Pentostatin	55-70	adenosine deaminase	Homo sapiens	74-93
3257147-1	1988	Interferon-alpha and the adenosine deaminase (ADA) inhibitor deoxycoformycin (dCF) have each been shown to be efficacious in the treatment of some lymphoid malignancies and to have potent antiproliferative activities in vitro.	Pentostatin	61-76	adenosine deaminase	Homo sapiens	25-44
3257147-1	1988	Interferon-alpha and the adenosine deaminase (ADA) inhibitor deoxycoformycin (dCF) have each been shown to be efficacious in the treatment of some lymphoid malignancies and to have potent antiproliferative activities in vitro.	Pentostatin	61-76	adenosine deaminase	Homo sapiens	46-49
3257147-1	1988	Interferon-alpha and the adenosine deaminase (ADA) inhibitor deoxycoformycin (dCF) have each been shown to be efficacious in the treatment of some lymphoid malignancies and to have potent antiproliferative activities in vitro.	Pentostatin	78-81	adenosine deaminase	Homo sapiens	25-44
3257147-1	1988	Interferon-alpha and the adenosine deaminase (ADA) inhibitor deoxycoformycin (dCF) have each been shown to be efficacious in the treatment of some lymphoid malignancies and to have potent antiproliferative activities in vitro.	Pentostatin	78-81	adenosine deaminase	Homo sapiens	46-49
3257147-3	1988	Treatment of Daudi cells for three to four days with doses of rIFN-alpha A that were growth inhibitory was unexpectedly found to increase the level of ADA activity per cell two- to threefold and therefore to prevent the inhibition of ADA by limiting concentrations of dCF.	Pentostatin	268-271	adenosine deaminase	Homo sapiens	151-154
3257147-3	1988	Treatment of Daudi cells for three to four days with doses of rIFN-alpha A that were growth inhibitory was unexpectedly found to increase the level of ADA activity per cell two- to threefold and therefore to prevent the inhibition of ADA by limiting concentrations of dCF.	Pentostatin	268-271	adenosine deaminase	Homo sapiens	234-237
3257147-4	1988	However, the opposite effects of dCF and rIFN-alpha A on ADA activity did not lead to antagonistic effects on growth inhibition.	Pentostatin	33-36	adenosine deaminase	Homo sapiens	57-60
3257147-5	1988	The higher concentrations of dCF (with deoxyadenosine) necessary for appreciable growth inhibition could inhibit the increased ADA activity in rIFN-alpha A-treated cells, thus resulting in additive antiproliferative effects.	Pentostatin	29-32	adenosine deaminase	Homo sapiens	127-130
2890401-1	1987	The adenosine deaminase inhibitor deoxycoformycin was used in low doses to treat 19 patients with clinically aggressive T cell malignancy with a mature membrane phenotype.	Pentostatin	34-49	adenosine deaminase	Homo sapiens	4-23
2825638-3	1987	These metabolic changes were suppressed in the presence of iodotubercidin (an inhibitor of adenosine kinase), but were reinforced in the presence of deoxycoformycin (an inhibitor of adenosine deaminase); 2-chloroadenosine induced no change in gluconeogenesis from lactate.	Pentostatin	149-164	adenosine deaminase	Rattus norvegicus	182-201
3499581-0	1987	Pharmacokinetics of 2"-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat.	Pentostatin	20-38	adenosine deaminase	Rattus norvegicus	56-75
3499581-1	1987	The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined.	Pentostatin	71-89	adenosine deaminase	Rattus norvegicus	44-63
3499581-1	1987	The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined.	Pentostatin	71-89	adenosine deaminase	Rattus norvegicus	65-68
3499581-1	1987	The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined.	Pentostatin	71-89	adenosine deaminase	Rattus norvegicus	143-146
3499581-1	1987	The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined.	Pentostatin	91-94	adenosine deaminase	Rattus norvegicus	44-63
3499581-1	1987	The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined.	Pentostatin	91-94	adenosine deaminase	Rattus norvegicus	65-68
3499581-1	1987	The distribution of the potent inhibitor of adenosine deaminase (ADA), 2"-deoxycoformycin (DCF), in the brain of the rat and its inhibition of ADA in brain and gut was determined.	Pentostatin	91-94	adenosine deaminase	Rattus norvegicus	143-146
3499581-5	1987	In brain, ADA was inhibited by about 95% at all three of these doses of DCF 2 hr after injection and activity returned to control levels by 30 days with the two smaller doses, but remained at 66% of control levels at 50 days with 18.6 mumol/kg.	Pentostatin	72-75	adenosine deaminase	Rattus norvegicus	10-13
3498118-5	1987	It was found that these inhibitors (EHNA and Ara-A, 2-deoxycoformycin and adenosine) increase the activity of serum biotinidase as was the case with ethionine.	Pentostatin	52-69	biotinidase	Rattus norvegicus	116-127
3332090-2	1987	Pentostatin is an inhibitor of adenosine deaminase, an enzyme that is important for purine metabolism, but more than one mechanism may be involved in its cytotoxic action.	Pentostatin	0-11	adenosine deaminase	Homo sapiens	31-50
3342099-4	1988	If ADA activity was blocked by 2"-deoxycoformycin (dCF, 5 microM), a tight-binding inhibitor of ADA, most of the Ado (96%) was incorporated into adenine nucleotides, whereas if Ado kinase activity was blocked with 5-iodotubercidin (10 microM), Ado was mainly (95%) metabolized into hypoxanthine.	Pentostatin	31-49	adenosine deaminase	Homo sapiens	96-99
3342099-4	1988	If ADA activity was blocked by 2"-deoxycoformycin (dCF, 5 microM), a tight-binding inhibitor of ADA, most of the Ado (96%) was incorporated into adenine nucleotides, whereas if Ado kinase activity was blocked with 5-iodotubercidin (10 microM), Ado was mainly (95%) metabolized into hypoxanthine.	Pentostatin	51-54	adenosine deaminase	Homo sapiens	3-6
3342099-4	1988	If ADA activity was blocked by 2"-deoxycoformycin (dCF, 5 microM), a tight-binding inhibitor of ADA, most of the Ado (96%) was incorporated into adenine nucleotides, whereas if Ado kinase activity was blocked with 5-iodotubercidin (10 microM), Ado was mainly (95%) metabolized into hypoxanthine.	Pentostatin	51-54	adenosine deaminase	Homo sapiens	96-99
3494649-6	1987	An involvement of adenosine in this response was demonstrated using an adenosine antagonist, caffeine, an uptake inhibitor, dipyridamole and an adenosine deaminase inhibitor, deoxycoformycin.	Pentostatin	175-190	adenosine deaminase	Rattus norvegicus	144-163
3829699-4	1987	A single topical dose with as low as 0.1% 2"-deoxycoformycin (dCF), an ADA inhibitor possessing immunosuppressive activity, was capable of totally inhibiting the corneal ADA activity.	Pentostatin	42-60	adenosine deaminase	Homo sapiens	71-74
3829699-4	1987	A single topical dose with as low as 0.1% 2"-deoxycoformycin (dCF), an ADA inhibitor possessing immunosuppressive activity, was capable of totally inhibiting the corneal ADA activity.	Pentostatin	42-60	adenosine deaminase	Homo sapiens	170-173
3829699-4	1987	A single topical dose with as low as 0.1% 2"-deoxycoformycin (dCF), an ADA inhibitor possessing immunosuppressive activity, was capable of totally inhibiting the corneal ADA activity.	Pentostatin	62-65	adenosine deaminase	Homo sapiens	71-74
3829699-4	1987	A single topical dose with as low as 0.1% 2"-deoxycoformycin (dCF), an ADA inhibitor possessing immunosuppressive activity, was capable of totally inhibiting the corneal ADA activity.	Pentostatin	62-65	adenosine deaminase	Homo sapiens	170-173
3829699-5	1987	Titration of the free dCF in the cornea following a single topical dose of 0.25% dCF indicated that enough dCF remained in the cornea 24 hrs after instillation to totally inhibit all corneal ADA plus 66 units of additional enzyme.	Pentostatin	81-84	adenosine deaminase	Homo sapiens	191-194
3829699-5	1987	Titration of the free dCF in the cornea following a single topical dose of 0.25% dCF indicated that enough dCF remained in the cornea 24 hrs after instillation to totally inhibit all corneal ADA plus 66 units of additional enzyme.	Pentostatin	81-84	adenosine deaminase	Homo sapiens	191-194
3500370-3	1987	The dATP concentrations in HCL, BCL and TCL increased from means of 2.9, 1.8 and 3.0 to 100.3, 68.2 and 51.3 pmol/10(6) cells respectively after 2 h with 10(-5) M dCF and 10(-4)M deoxyadenosine.	Pentostatin	163-166	ras homolog family member J	Homo sapiens	40-43
3488805-1	1986	Pentostatin (dCF), an inhibitor of adenosine deaminase, has shown activity in the treatment of several lymphoid malignancies, even in the earliest phase I trials.	Pentostatin	0-11	adenosine deaminase	Homo sapiens	35-54
3097141-8	1987	Primary MLC was completely inhibited by concentrations as low as 1 microM dCF and 1 microM AdR.	Pentostatin	74-77	modulator of VRAC current 1	Homo sapiens	8-11
3097141-12	1987	In secondary MLC, IL 2 production was markedly reduced in the presence of 9 microM dCF and 60 microM AdR.	Pentostatin	83-86	modulator of VRAC current 1	Homo sapiens	13-16
3097141-12	1987	In secondary MLC, IL 2 production was markedly reduced in the presence of 9 microM dCF and 60 microM AdR.	Pentostatin	83-86	interleukin 2	Homo sapiens	18-22
3097141-15	1987	In phytohemagglutinin (PHA)-stimulated cultures, 9 microM dCF and 60 microM AdR resulted in inhibition of proliferation and IL 2 receptor expression, whereas IL 2 production was normal.	Pentostatin	58-61	interleukin 2	Homo sapiens	124-128
3097141-15	1987	In phytohemagglutinin (PHA)-stimulated cultures, 9 microM dCF and 60 microM AdR resulted in inhibition of proliferation and IL 2 receptor expression, whereas IL 2 production was normal.	Pentostatin	58-61	interleukin 2	Homo sapiens	158-162
3488805-1	1986	Pentostatin (dCF), an inhibitor of adenosine deaminase, has shown activity in the treatment of several lymphoid malignancies, even in the earliest phase I trials.	Pentostatin	13-16	adenosine deaminase	Homo sapiens	35-54
3486057-1	1986	The metabolic changes induced by the deoxycoformycin inhibition of adenosine deaminase were studied in human erythrocytes incubated with nucleosides.	Pentostatin	37-52	adenosine deaminase	Homo sapiens	67-86
2428625-10	1986	It is identical to the activity of C57BL/6 thymic cells or C57BL/6 T tumor lines regarding its sensitivity to ADA inhibitors 2-deoxycoformycin and erythro-9-(2-hydroxyl-3-nonyl)adenine, and its electrophoretic mobility under nondenaturing conditions (starch gel and isoelectric focusing).	Pentostatin	125-142	adenosine deaminase	Mus musculus	110-113
3011239-2	1986	Recent studies have shown that hairy cell leukemia (HCL) may respond to treatment with the ADA inhibitor, 2-deoxycoformycin.	Pentostatin	106-123	adenosine deaminase	Homo sapiens	91-94
2939873-1	1986	Two elderly patients with prolymphocytic leukaemia (PLL) of T helper phenotype were treated with the adenosine deaminase inhibitor--deoxycoformycin--and achieved remission.	Pentostatin	132-147	adenosine deaminase	Homo sapiens	101-120
3486414-2	1986	Cells that incorporate the gene can be selected by growth in the presence of low concentrations of the ADA inhibitor 2"-deoxycoformycin with cytotoxic concentrations of adenosine or its analogue 9-beta-D-xylofuranosyl adenine.	Pentostatin	117-135	adenosine deaminase	Homo sapiens	103-106
3486414-3	1986	The DNA copy number of the transfected ADA minigene in the isolated transformants of Chinese hamster ovary cells can be amplified greater than 100-fold by growth in ADA selection media and increasing concentrations of 2"-deoxycoformycin.	Pentostatin	218-236	adenosine deaminase	Cricetulus griseus	39-42
3515350-3	1986	2"-Deoxycoformycin was added to inhibit endogenous adenosine deaminase activity (maximal suppression was achieved at 0.8 microM concentration of the inhibitor).	Pentostatin	0-18	adenosine deaminase	Rattus norvegicus	51-70
2870121-6	1986	In medium supplemented with deoxycoformycin, a tight binding ADA inhibitor, dAdo retarded DNA rejoining in a dose and time dependent manner.	Pentostatin	28-43	ado	Drosophila melanogaster	76-80
3485513-4	1986	Stable resistance to dCF is acquired in rat cells by overproduction of the enzyme adenosine deaminase (ADA) as a result of amplification of ADA gene sequences.	Pentostatin	21-24	adenosine deaminase	Rattus norvegicus	82-101
2433905-5	1986	The enzyme-inhibitor complex between adenosine deaminase and 2"-chloropentostatin was much more rapidly dissociable than the complex with pentostatin.	Pentostatin	70-81	adenosine deaminase	Homo sapiens	37-56
2433905-6	1986	The complex between adenosine deaminase and 2"-chloropentostatin dissociated with a half-life of approximately 3 hr, compared with 68 hr for the complex between adenosine deaminase and pentostatin.	Pentostatin	53-64	adenosine deaminase	Homo sapiens	20-39
2433905-6	1986	The complex between adenosine deaminase and 2"-chloropentostatin dissociated with a half-life of approximately 3 hr, compared with 68 hr for the complex between adenosine deaminase and pentostatin.	Pentostatin	53-64	adenosine deaminase	Homo sapiens	161-180
3485513-4	1986	Stable resistance to dCF is acquired in rat cells by overproduction of the enzyme adenosine deaminase (ADA) as a result of amplification of ADA gene sequences.	Pentostatin	21-24	adenosine deaminase	Rattus norvegicus	103-106
3485513-4	1986	Stable resistance to dCF is acquired in rat cells by overproduction of the enzyme adenosine deaminase (ADA) as a result of amplification of ADA gene sequences.	Pentostatin	21-24	adenosine deaminase	Rattus norvegicus	140-143
3877709-1	1985	In rat lymph node lymphocytes stimulated for 24 h by concanavalin A in the presence of 10(-5) M 2"-deoxycoformycin (a potent inhibitor of adenosine deaminase) and 10(-5) M 2"-deoxyadenosine the adenylic nucleotide pool was reduced by 55.5% without modification of either the adenylic energy charge or the ability of the cells to liberate interleukin 2.	Pentostatin	96-114	adenosine deaminase	Rattus norvegicus	138-157
3840153-4	1985	The aglycone of adechlorin was identical with that of the known adenosine deaminase inhibitors coformycin and 2"-deoxycoformycin.	Pentostatin	110-128	adenosine deaminase	Mus musculus	64-83
3875570-10	1985	In addition, the antiproliferative effect of both core compounds and their corresponding nucleosides could be potentiated by the addition of the adenosine deaminase inhibitor, deoxycoformycin.	Pentostatin	176-191	adenosine deaminase	Homo sapiens	145-164
3840153-6	1985	The Ki values for adechlorin, coformycin and 2"-deoxycoformycin against adenosine deaminase were determined to be 5.3 X 10(-10) M, 2.1 X 10(-10) M and 7.6 X 10(-11) M, respectively.	Pentostatin	45-63	adenosine deaminase	Mus musculus	72-91
2981904-6	1985	The application of 2"-deoxycoformycin, a specific inhibitor of adenosine deaminase, and the potential usefulness of two other enzymes as targets for treatment with selective agents is discussed.	Pentostatin	19-37	adenosine deaminase	Homo sapiens	63-82
3873908-0	1985	Adenosine deaminase gene amplification in deoxycoformycin-resistant mammalian cells.	Pentostatin	42-57	adenosine deaminase	Homo sapiens	0-19
3873908-1	1985	Deoxycoformycin (dCF)-resistant mutants of rat hepatoma, mouse LMTK-, and Chinese hamster ovary (CHO) cells have been isolated and shown to overproduce adenosine deaminase (ADA).	Pentostatin	0-15	adenosine deaminase	Cricetulus griseus	152-171
3873908-1	1985	Deoxycoformycin (dCF)-resistant mutants of rat hepatoma, mouse LMTK-, and Chinese hamster ovary (CHO) cells have been isolated and shown to overproduce adenosine deaminase (ADA).	Pentostatin	0-15	adenosine deaminase	Cricetulus griseus	173-176
3873908-1	1985	Deoxycoformycin (dCF)-resistant mutants of rat hepatoma, mouse LMTK-, and Chinese hamster ovary (CHO) cells have been isolated and shown to overproduce adenosine deaminase (ADA).	Pentostatin	17-20	adenosine deaminase	Cricetulus griseus	152-171
3873908-1	1985	Deoxycoformycin (dCF)-resistant mutants of rat hepatoma, mouse LMTK-, and Chinese hamster ovary (CHO) cells have been isolated and shown to overproduce adenosine deaminase (ADA).	Pentostatin	17-20	adenosine deaminase	Cricetulus griseus	173-176
3873908-4	1985	When dCF-resistant rat hepatoma and mouse cells are selected by increasing the concentration of the inhibitor in small increments, there is a good correlation between the increase in ADA gene copy number and the increase in the level of expression of ADA, suggesting that all of the amplified genes are equally active in the expression of ADA.	Pentostatin	5-8	adenosine deaminase	Mus musculus	183-186
3873908-4	1985	When dCF-resistant rat hepatoma and mouse cells are selected by increasing the concentration of the inhibitor in small increments, there is a good correlation between the increase in ADA gene copy number and the increase in the level of expression of ADA, suggesting that all of the amplified genes are equally active in the expression of ADA.	Pentostatin	5-8	adenosine deaminase	Mus musculus	251-254
3873908-4	1985	When dCF-resistant rat hepatoma and mouse cells are selected by increasing the concentration of the inhibitor in small increments, there is a good correlation between the increase in ADA gene copy number and the increase in the level of expression of ADA, suggesting that all of the amplified genes are equally active in the expression of ADA.	Pentostatin	5-8	adenosine deaminase	Mus musculus	251-254
3872599-3	1985	Adult AKR/J mice were treated with 10 micrograms/g or 100 micrograms/g 2"-deoxycoformycin, an adenosine deaminase inhibitor with chemotherapeutic potential.	Pentostatin	71-89	adenosine deaminase	Homo sapiens	94-113
2579098-1	1985	Deoxyadenosine has been implicated as the toxic metabolite causing profound lymphopenia in immunodeficient children with a genetic deficiency of adenosine deaminase (ADA), and in adults treated with the potent ADA inhibitor deoxycoformycin.	Pentostatin	224-239	adenosine deaminase	Homo sapiens	210-213
2985893-5	1985	Addition of adenosine deaminase reduced responses only to adenosine and 5"-AMP, while inhibition of adenosine deaminase with deoxycoformycin potentiated responses only to 5"-AMP and 5"-ADP.	Pentostatin	125-140	adenosine deaminase	Cavia porcellus	100-119
3873254-0	1985	Spontaneous epimerization of (S)-deoxycoformycin and interaction of (R)-deoxycoformycin, (S)-deoxycoformycin, and 8-ketodeoxycoformycin with adenosine deaminase.	Pentostatin	68-87	adenosine deaminase	Bos taurus	141-160
3874406-0	1985	Effects of adenosine deaminase inhibitor 2"-deoxycoformycin on the repair and expression of potentially lethal damage sensitive to beta-araA.	Pentostatin	41-59	adenosine deaminase	Homo sapiens	11-30
3878116-0	1985	Inhibition of interleukin-2 messenger RNA in mouse lymphocytes by 2"-deoxycoformycin and adenosine metabolites.	Pentostatin	66-84	interleukin 2	Mus musculus	14-27
3881043-2	1985	Production of labeled inosine and hypoxanthine from adenosine was considerably lower in adenosine deaminase (ADA)-deficient cells than in normal cells and virtually eliminated in normal cells by the presence of 1 microM deoxycoformycin (a potent ADA inhibitor), suggesting that labeled inosine and hypoxanthine production requires ADA activity.	Pentostatin	220-235	adenosine deaminase	Homo sapiens	88-107
3881043-2	1985	Production of labeled inosine and hypoxanthine from adenosine was considerably lower in adenosine deaminase (ADA)-deficient cells than in normal cells and virtually eliminated in normal cells by the presence of 1 microM deoxycoformycin (a potent ADA inhibitor), suggesting that labeled inosine and hypoxanthine production requires ADA activity.	Pentostatin	220-235	adenosine deaminase	Homo sapiens	109-112
3881043-2	1985	Production of labeled inosine and hypoxanthine from adenosine was considerably lower in adenosine deaminase (ADA)-deficient cells than in normal cells and virtually eliminated in normal cells by the presence of 1 microM deoxycoformycin (a potent ADA inhibitor), suggesting that labeled inosine and hypoxanthine production requires ADA activity.	Pentostatin	220-235	adenosine deaminase	Homo sapiens	246-249
3881043-2	1985	Production of labeled inosine and hypoxanthine from adenosine was considerably lower in adenosine deaminase (ADA)-deficient cells than in normal cells and virtually eliminated in normal cells by the presence of 1 microM deoxycoformycin (a potent ADA inhibitor), suggesting that labeled inosine and hypoxanthine production requires ADA activity.	Pentostatin	220-235	adenosine deaminase	Homo sapiens	246-249
3877119-1	1985	Pentostatin (2"-deoxycoformycin), a potent inhibitor of adenosine deaminase, was administered therapeutically to rats with type II collagen-induced arthritis and the effects on hindpaw swelling, serum haptoglobin concentration, and anticollagen antibody titer determined.	Pentostatin	0-11	adenosine deaminase	Rattus norvegicus	56-75
3877119-1	1985	Pentostatin (2"-deoxycoformycin), a potent inhibitor of adenosine deaminase, was administered therapeutically to rats with type II collagen-induced arthritis and the effects on hindpaw swelling, serum haptoglobin concentration, and anticollagen antibody titer determined.	Pentostatin	13-31	adenosine deaminase	Rattus norvegicus	56-75
3877119-2	1985	Daily intraperitoneal administration of pentostatin at 10.0 or 1.0 mg/kg/day for three weeks produced significant enhancement of hind-paw swelling and elevation of serum haptoglobin.	Pentostatin	40-51	haptoglobin	Rattus norvegicus	170-181
6334522-2	1984	The assay of residual adenosine deaminase (ADA) activity was used as a sensitive measure of the transport of deoxycoformycin (dCF) into human erythrocytes.	Pentostatin	109-124	adenosine deaminase	Homo sapiens	22-41
6334686-2	1984	It was found that in the presence of deoxycoformycin, an inhibitor of adenosine deaminase, deoxyadenosine was the only product of deoxy-ATP catabolism.	Pentostatin	37-52	adenosine deaminase	Homo sapiens	70-89
6334522-2	1984	The assay of residual adenosine deaminase (ADA) activity was used as a sensitive measure of the transport of deoxycoformycin (dCF) into human erythrocytes.	Pentostatin	109-124	adenosine deaminase	Homo sapiens	43-46
6334522-2	1984	The assay of residual adenosine deaminase (ADA) activity was used as a sensitive measure of the transport of deoxycoformycin (dCF) into human erythrocytes.	Pentostatin	126-129	adenosine deaminase	Homo sapiens	22-41
6334522-2	1984	The assay of residual adenosine deaminase (ADA) activity was used as a sensitive measure of the transport of deoxycoformycin (dCF) into human erythrocytes.	Pentostatin	126-129	adenosine deaminase	Homo sapiens	43-46
6334522-3	1984	Contrary to prior reports from this laboratory, the inactivation of intraerythrocytic ADA by dCF was linear rather than log-linear, with time.	Pentostatin	93-96	adenosine deaminase	Homo sapiens	86-89
6202772-4	1984	BAL 9, a lymphoma of the Lyt-1+,2+ T cell phenotype, was the most sensitive to DCF in vivo, and its DNA synthesis was inhibited more than 95% when cultured in the presence of dAr and DCF in vitro.	Pentostatin	79-82	CD5 antigen	Mus musculus	25-30
6236916-2	1984	On this basis, patients with T cell malignancies have been treated with the ADA inhibitor, deoxycoformycin.	Pentostatin	91-106	adenosine deaminase	Homo sapiens	76-79
6610485-1	1984	The biochemical mechanism of lymphocyte dysfunction with adenosine deaminase deficiency has been investigated using cultured phytohemagglutinin stimulated normal peripheral blood lymphocytes and the adenosine deaminase (ADA) inhibitor 2"-deoxycoformycin.	Pentostatin	235-253	adenosine deaminase	Homo sapiens	57-76
6204981-2	1984	The biochemical and metabolic effects of deoxycoformycin, a potent inhibitor of adenosine deaminase, were investigated using two human T lymphoblastoid cell lines.	Pentostatin	41-56	adenosine deaminase	Homo sapiens	80-99
6424986-2	1984	Only 2"-deoxycoformycin (dCF) completely inhibited ADA in T and B cells at concentrations in excess of 5 microM.	Pentostatin	5-23	adenosine deaminase	Homo sapiens	51-54
6610419-1	1984	An analytical method for determination of 2"-deoxycoformycin (2"-DCF) concentrations in plasma and urine was developed based upon a modification of adenosine deaminase (ADA) inhibition assays described in the literature.	Pentostatin	42-60	adenosine deaminase	Homo sapiens	169-172
6610419-1	1984	An analytical method for determination of 2"-deoxycoformycin (2"-DCF) concentrations in plasma and urine was developed based upon a modification of adenosine deaminase (ADA) inhibition assays described in the literature.	Pentostatin	62-68	adenosine deaminase	Homo sapiens	148-167
6610419-1	1984	An analytical method for determination of 2"-deoxycoformycin (2"-DCF) concentrations in plasma and urine was developed based upon a modification of adenosine deaminase (ADA) inhibition assays described in the literature.	Pentostatin	62-68	adenosine deaminase	Homo sapiens	169-172
6610419-6	1984	Quantitation of 2"-DCF in patient samples is accomplished by an ADA inhibition titration technique in which the spectrophotometrically determined absorbance change is related to the two independent variables, the concentration of 2"-DCF in the standards and the relative time of the analysis.	Pentostatin	16-22	adenosine deaminase	Homo sapiens	64-67
6424986-2	1984	Only 2"-deoxycoformycin (dCF) completely inhibited ADA in T and B cells at concentrations in excess of 5 microM.	Pentostatin	25-28	adenosine deaminase	Homo sapiens	51-54
6362851-2	1984	In the presence of dipyridamole and 2"-deoxyadenosine and when adenosine deaminase was inhibited with deoxycoformycin, the L1210 leukemia cell which is a non-T-, non-B-cell type accumulated dATP like a T-cell type.	Pentostatin	102-117	adenosine deaminase	Mus musculus	63-82
6609048-7	1984	Adenosine levels were maintained in the perfusate by two methods: (1) addition of fresh perfusate or (2) pretreatment of the kidney with the adenosine deaminase inhibitor--deoxycoformycin.	Pentostatin	172-187	adenosine deaminase	Canis lupus familiaris	141-160
6607471-0	1984	Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2"-deoxycoformycin.	Pentostatin	121-139	adenosine deaminase	Homo sapiens	91-110
6609525-0	1984	Adenosine deaminase in malaria infection: effect of 2"-deoxycoformycin in vivo.	Pentostatin	52-70	adenosine deaminase	Homo sapiens	0-19
6609531-0	1984	Deoxycoformycin resistant mammalian cells that overproduce adenosine deaminase.	Pentostatin	0-15	adenosine deaminase	Homo sapiens	59-78
6606032-1	1983	Pentostatin (I), a tight-binding inhibitor of adenosine deaminase, was evaluated in combination with the partially effective antitumor nucleoside N6-(delta 2-isopentenyl)adenosine (II) for cytotoxic activity against cultured L-1210 lymphocytic mouse leukemia cells.	Pentostatin	0-11	adenosine deaminase	Mus musculus	46-65
6414755-6	1983	Defibrination before nucleotide extraction of mononuclear cells from a patient with T-cell leukaemic/lymphoma treated with the ADA inhibitor deoxycoformycin enabled the demonstration of grossly raised deoxy-ATP levels relative to deoxy-ADP levels (ratio 16.1:1), associated with severe ATP depletion.	Pentostatin	141-156	adenosine deaminase	Homo sapiens	127-130
6605347-0	1983	Amplification of adenosine deaminase gene sequences in deoxycoformycin-resistant rat hepatoma cells.	Pentostatin	55-70	adenosine deaminase	Rattus norvegicus	17-36
6605347-1	1983	Deoxycoformycin-resistant rat hepatoma cells exhibit up to a 2000-fold increase in adenosine deaminase activity compared to the sensitive parental cells.	Pentostatin	0-15	adenosine deaminase	Rattus norvegicus	83-102
6605347-4	1983	Using this cDNA as a specific hybridization probe, all deoxycoformycin-resistant variants were shown to have increased amounts of adenosine deaminase mRNA and gene sequences.	Pentostatin	55-70	adenosine deaminase	Rattus norvegicus	130-149
6605347-6	1983	However, the degree of adenosine deaminase gene amplification in one deoxycoformycin-resistant cell line (6-10-200) was 3-4-fold less than the relative increase in adenosine deaminase mRNA.	Pentostatin	69-84	adenosine deaminase	Rattus norvegicus	23-42
6605347-7	1983	These results indicate that the increased adenosine deaminase activity in deoxycoformycin-resistant rat hepatoma cells is due in large part, but not exclusively, to gene amplification.	Pentostatin	74-89	adenosine deaminase	Rattus norvegicus	42-61
6358608-0	1983	Morphologic changes and immunohistochemical localization of adenosine deaminase in tissues of rats given injections of 2"-deoxycoformycin.	Pentostatin	119-137	adenosine deaminase	Rattus norvegicus	60-79
6358608-1	1983	2"-Deoxycoformycin (DCF) is a potent inhibitor of adenosine deaminase (ADA) and a potential antineoplastic and immunosuppressive agent.	Pentostatin	0-18	adenosine deaminase	Rattus norvegicus	50-69
6358608-1	1983	2"-Deoxycoformycin (DCF) is a potent inhibitor of adenosine deaminase (ADA) and a potential antineoplastic and immunosuppressive agent.	Pentostatin	0-18	adenosine deaminase	Rattus norvegicus	71-74
6358608-1	1983	2"-Deoxycoformycin (DCF) is a potent inhibitor of adenosine deaminase (ADA) and a potential antineoplastic and immunosuppressive agent.	Pentostatin	20-23	adenosine deaminase	Rattus norvegicus	50-69
6358608-1	1983	2"-Deoxycoformycin (DCF) is a potent inhibitor of adenosine deaminase (ADA) and a potential antineoplastic and immunosuppressive agent.	Pentostatin	20-23	adenosine deaminase	Rattus norvegicus	71-74
6358608-2	1983	In this study the kinetics of ADA expression was assessed by immunomorphologic and enzymatic methods in tissues of ACI rats given injections of DCF.	Pentostatin	144-147	adenosine deaminase	Rattus norvegicus	30-33
6311934-9	1983	Inactivation of ADA with DCF abrogated the enhancement of superoxide anion generation.	Pentostatin	25-28	adenosine deaminase	Homo sapiens	16-19
6603264-0	1983	Effect of 2"-deoxycoformycin infusion on S-adenosylhomocysteine hydrolase and the amount of S-adenosylhomocysteine and related compounds in tissues of mice.	Pentostatin	10-28	S-adenosylhomocysteine hydrolase	Mus musculus	41-73
6602803-7	1983	We used 11AAU selection in conjunction with stepwise selection for increasing resistance to deoxycoformycin, an adenosine deaminase inhibitor, to obtain highly drug-resistant cells with a 6000-fold increase in adenosine deaminase activity.	Pentostatin	92-107	adenosine deaminase	Mus musculus	112-131
6604525-1	1983	Rat polymorphonuclear leucocytes or neonatal-rat heart cells in culture were treated with 2"-deoxycoformycin and 5-iodotubercidin at concentrations that inhibited adenosine deaminase (EC 3.5.4.4) and adenosine kinase (EC 2.7.1.20) inside the intact cells, and the rate of adenosine accumulation was determined.	Pentostatin	90-108	adenosine deaminase	Rattus norvegicus	163-182
6347398-2	1983	The effect of deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase, on the ability of mouse spleen cells to generate antibody responses in vitro has been examined.	Pentostatin	14-29	adenosine deaminase	Mus musculus	59-78
6347398-2	1983	The effect of deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase, on the ability of mouse spleen cells to generate antibody responses in vitro has been examined.	Pentostatin	31-34	adenosine deaminase	Mus musculus	59-78
6609231-4	1984	Despite extensive rinsing of tissues, adenosine deaminase leaked into the incubation media, requiring its inhibition by 5 nM deoxycoformycin.	Pentostatin	125-140	adenosine deaminase	Oryctolagus cuniculus	38-57
6602803-7	1983	We used 11AAU selection in conjunction with stepwise selection for increasing resistance to deoxycoformycin, an adenosine deaminase inhibitor, to obtain highly drug-resistant cells with a 6000-fold increase in adenosine deaminase activity.	Pentostatin	92-107	adenosine deaminase	Mus musculus	210-229
6602803-8	1983	Adenosine deaminase accounted for approximately 50% of the soluble protein in highly drug-resistant lines and was indistinguishable from that in the parent as judged by isoelectric focusing, electrophoretic mobility on starch gels, and by deoxycoformycin binding studies.	Pentostatin	239-254	adenosine deaminase	Mus musculus	0-19
6601986-1	1983	A patient with refractory T-cell acute lymphoblastic leukemia was treated with eight courses of the adenosine deaminase inhibitor, 2"-deoxycoformycin (dCF), over a 5-month period.	Pentostatin	131-149	adenosine deaminase	Homo sapiens	100-119
6601986-1	1983	A patient with refractory T-cell acute lymphoblastic leukemia was treated with eight courses of the adenosine deaminase inhibitor, 2"-deoxycoformycin (dCF), over a 5-month period.	Pentostatin	151-154	adenosine deaminase	Homo sapiens	100-119
6303563-3	1983	The minimal ADA activity in DHL-9 extracts, 0.028 nmol/min/mg protein, was less than 50% of the activity in two B-lymphoblastoid cell lines from ADA-deficient patients and was resistant to the potent ADA inhibitor deoxycoformycin.	Pentostatin	214-229	adenosine deaminase	Homo sapiens	12-15
6604884-1	1983	The tight-binding adenosine deaminase inhibitor, 2"-deoxycoformycin (dCF), was continuously infused into mice by intraperitoneal implantation of microosmotic pumps delivering the compound at a rate of 0.16 mg hr-1 kg-1 for up to 6 days.	Pentostatin	49-67	adenosine deaminase	Mus musculus	18-37
6604884-1	1983	The tight-binding adenosine deaminase inhibitor, 2"-deoxycoformycin (dCF), was continuously infused into mice by intraperitoneal implantation of microosmotic pumps delivering the compound at a rate of 0.16 mg hr-1 kg-1 for up to 6 days.	Pentostatin	69-72	adenosine deaminase	Mus musculus	18-37
6289941-1	1982	Leukemic cells incubated in vitro with 2"-deoxyadenosine (dAdo) plus an inhibitor of adenosine deaminase, 2"-deoxy-coformycin (DCF), show different metabolic responses depending on the histologic and immunologic type of the leukemia.	Pentostatin	106-125	adenosine deaminase	Homo sapiens	85-104
6600401-1	1983	We have investigated the use of 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF).	Pentostatin	32-50	adenosine deaminase	Homo sapiens	80-99
6600401-1	1983	We have investigated the use of 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF).	Pentostatin	32-50	adenosine deaminase	Homo sapiens	101-104
6600401-1	1983	We have investigated the use of 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF).	Pentostatin	52-55	adenosine deaminase	Homo sapiens	80-99
6600401-1	1983	We have investigated the use of 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase (ADA), in the treatment of 4 patients with advanced mycosis fungoides (MF).	Pentostatin	52-55	adenosine deaminase	Homo sapiens	101-104
6600234-0	1983	Increased adenosine deaminase synthesis and messenger RNA activity in deoxycoformycin-resistant cells.	Pentostatin	70-85	adenosine deaminase	Rattus norvegicus	10-29
6600234-1	1983	The basis for the increased adenosine deaminase activity in deoxycoformycin-resistant rat hepatoma cells was investigated.	Pentostatin	60-75	adenosine deaminase	Rattus norvegicus	28-47
6815190-0	1982	Adenosine deaminase from deoxycoformycin-sensitive and -resistant rat hepatoma cells.	Pentostatin	25-40	adenosine deaminase	Rattus norvegicus	0-19
6815190-2	1982	Deoxycoformycin-resistant rat hepatoma cells exhibit up to 300-fold increase in adenosine deaminase activity compared to the sensitive parental cells.	Pentostatin	0-15	adenosine deaminase	Rattus norvegicus	80-99
6815190-3	1982	In order to determine the basis of the increased enzyme activity in deoxycoformycin-resistant cells, adenosine deaminase was purified from rat liver and deoxycoformycin-sensitive and -resistant cells.	Pentostatin	68-83	adenosine deaminase	Rattus norvegicus	101-120
6815190-3	1982	In order to determine the basis of the increased enzyme activity in deoxycoformycin-resistant cells, adenosine deaminase was purified from rat liver and deoxycoformycin-sensitive and -resistant cells.	Pentostatin	153-168	adenosine deaminase	Rattus norvegicus	101-120
6815190-9	1982	These data indicate that deoxycoformycin-resistant rat hepatoma cells produce increased amounts of adenosine deaminase protein which results in increased enzymatic activity.	Pentostatin	25-40	adenosine deaminase	Rattus norvegicus	99-118
6980706-1	1982	It has been suggested that, by inhibiting the adenosine deaminase (ADA)-mediated catabolism of 9-beta-D-arabinofuranosyladenine (ara-A), 2"-deoxycoformycin (DCF) would increase the half-life (t1/2) of ara-A, a compound with known antileukemic activity.	Pentostatin	137-155	adenosine deaminase	Homo sapiens	46-65
6296645-1	1982	Ara-C at very low dosage has been reported to decrease the host toxicity of ara-AMP or ara-A in combination with 2"-deoxycoformycin, a potent adenosine deaminase inhibitor, while increasing the toxicity to intracerebral L1210 leukemia.	Pentostatin	113-131	ATP binding cassette subfamily C member 6	Homo sapiens	0-3
6980706-1	1982	It has been suggested that, by inhibiting the adenosine deaminase (ADA)-mediated catabolism of 9-beta-D-arabinofuranosyladenine (ara-A), 2"-deoxycoformycin (DCF) would increase the half-life (t1/2) of ara-A, a compound with known antileukemic activity.	Pentostatin	137-155	adenosine deaminase	Homo sapiens	67-70
6980706-1	1982	It has been suggested that, by inhibiting the adenosine deaminase (ADA)-mediated catabolism of 9-beta-D-arabinofuranosyladenine (ara-A), 2"-deoxycoformycin (DCF) would increase the half-life (t1/2) of ara-A, a compound with known antileukemic activity.	Pentostatin	157-160	adenosine deaminase	Homo sapiens	46-65
6980706-1	1982	It has been suggested that, by inhibiting the adenosine deaminase (ADA)-mediated catabolism of 9-beta-D-arabinofuranosyladenine (ara-A), 2"-deoxycoformycin (DCF) would increase the half-life (t1/2) of ara-A, a compound with known antileukemic activity.	Pentostatin	157-160	adenosine deaminase	Homo sapiens	67-70
6980706-9	1982	These data confirm that the kinetics of ara-A catabolism can be altered by inhibition of ADA and suggest that more than one dose of DCF may be necessary for complete inhibition of the enzyme and optimal pharmacological modulation of ara-A.	Pentostatin	132-135	adenosine deaminase	Homo sapiens	89-92
6977672-1	1982	2"-Deoxycoformycin (DCF) is an inhibitor of the enzyme adenosine deaminase (ADA) and has shown promise as an antileukemia agent.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	55-74
6981855-0	1982	Isolation of deoxycoformycin-resistant cells with increased levels of adenosine deaminase.	Pentostatin	13-28	adenosine deaminase	Homo sapiens	70-89
6981855-1	1982	Deoxycoformycin (dCF) is a specific inhibitor of adenosine deaminase (ADA).	Pentostatin	0-15	adenosine deaminase	Homo sapiens	49-68
6981855-1	1982	Deoxycoformycin (dCF) is a specific inhibitor of adenosine deaminase (ADA).	Pentostatin	17-20	adenosine deaminase	Homo sapiens	49-68
6981855-5	1982	Initially, dCF-resistant cell lines have 3-10 times the level of adenosine deaminase when compared to sensitive parental cells.	Pentostatin	11-14	adenosine deaminase	Homo sapiens	65-84
6980005-1	1982	The accumulation of deoxyadenosine triphosphate (dATP) in erythrocytes of mice treated with the adenosine deaminase inhibitor deoxycoformycin was studied in an attempt to establish and evaluate a model system for the study of at least some biochemical aspects of hereditary adenosine deaminase deficiency.	Pentostatin	126-141	adenosine deaminase	Mus musculus	96-115
6283540-1	1982	Loss of ATP accompanying accumulation of dATP has recently been reported to occur in the erythrocytes and lymphoblasts of patients with T lymphocytic leukemia during treatment with deoxycoformycin, an inhibitor of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) that causes the accumulation of deoxyadenosine.	Pentostatin	181-196	adenosine deaminase	Homo sapiens	214-233
6283540-1	1982	Loss of ATP accompanying accumulation of dATP has recently been reported to occur in the erythrocytes and lymphoblasts of patients with T lymphocytic leukemia during treatment with deoxycoformycin, an inhibitor of adenosine deaminase (adenosine aminohydrolase, EC 3.5.4.4) that causes the accumulation of deoxyadenosine.	Pentostatin	181-196	adenosine deaminase	Homo sapiens	235-259
6977672-1	1982	2"-Deoxycoformycin (DCF) is an inhibitor of the enzyme adenosine deaminase (ADA) and has shown promise as an antileukemia agent.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	76-79
6977672-1	1982	2"-Deoxycoformycin (DCF) is an inhibitor of the enzyme adenosine deaminase (ADA) and has shown promise as an antileukemia agent.	Pentostatin	20-23	adenosine deaminase	Homo sapiens	55-74
6977672-1	1982	2"-Deoxycoformycin (DCF) is an inhibitor of the enzyme adenosine deaminase (ADA) and has shown promise as an antileukemia agent.	Pentostatin	20-23	adenosine deaminase	Homo sapiens	76-79
6263381-1	1981	Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA).	Pentostatin	0-15	adenosine deaminase	Homo sapiens	41-60
6275991-0	1982	Relationship of 5"-nucleotidase activity and antileukemic effect in 2"-deoxycoformycin therapy.	Pentostatin	68-86	5'-nucleotidase ecto	Homo sapiens	16-31
6977170-4	1982	Deoxycoformycin, an adenosine analog which is a potent inhibitor of adenosine deaminase, has shown moderate activity in acute leukemia patients in phase I trials, and has the potential to produce synergistic antitumor toxicity when used with arabinofuranosyladenine.	Pentostatin	0-15	adenosine deaminase	Homo sapiens	68-87
6263381-1	1981	Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA).	Pentostatin	0-15	adenosine deaminase	Homo sapiens	62-65
6263381-1	1981	Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA).	Pentostatin	17-20	adenosine deaminase	Homo sapiens	41-60
6263381-1	1981	Deoxycoformycin (DCF) is an inhibitor of adenosine deaminase (ADA).	Pentostatin	17-20	adenosine deaminase	Homo sapiens	62-65
6972800-1	1981	The in vitro effects of deoxyadenosine and an adenosine deaminase inhibitor, deoxycoformycin, on the synthesis of DNA and the metabolism of purines were investigated in human leukemic T-cells.	Pentostatin	77-92	adenosine deaminase	Homo sapiens	46-65
6969403-2	1980	We have administered 2"-deoxycoformycin, a potent inhibitor of adenosine deaminase, to a patient with a lymphoproliferative malignancy.	Pentostatin	21-39	adenosine deaminase	Homo sapiens	63-82
6259294-2	1981	2"-Deoxycoformycin (2"-DCF), an adenosine deaminase inhibitor, slightly increased basal, adenosine, and norepinephrine-elicited accumulations of cyclic AMP, whereas dipyridamole, an uptake inhibitor, had an even greater effect on cyclic AMP accumulations under the same conditions.	Pentostatin	0-18	adenosine deaminase	Rattus norvegicus	32-51
6259294-2	1981	2"-Deoxycoformycin (2"-DCF), an adenosine deaminase inhibitor, slightly increased basal, adenosine, and norepinephrine-elicited accumulations of cyclic AMP, whereas dipyridamole, an uptake inhibitor, had an even greater effect on cyclic AMP accumulations under the same conditions.	Pentostatin	20-26	adenosine deaminase	Rattus norvegicus	32-51
6975188-1	1981	Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation.	Pentostatin	0-15	adenosine deaminase	Homo sapiens	54-73
6975188-1	1981	Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation.	Pentostatin	0-15	adenosine deaminase	Homo sapiens	75-78
6975188-1	1981	Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation.	Pentostatin	17-20	adenosine deaminase	Homo sapiens	54-73
6975188-1	1981	Deoxycoformycin (DCF) is a tight-binding inhibitor of adenosine deaminase (ADA) currently undergoing phase I--II evaluation.	Pentostatin	17-20	adenosine deaminase	Homo sapiens	75-78
7018725-2	1981	2"-deoxycoformycin (2"-dCF) is a powerful inhibitor of adenosine deaminase (ADA), an enzyme found in high concentrations in lymphoid tissue.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	55-74
7018725-2	1981	2"-deoxycoformycin (2"-dCF) is a powerful inhibitor of adenosine deaminase (ADA), an enzyme found in high concentrations in lymphoid tissue.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	76-79
7018725-2	1981	2"-deoxycoformycin (2"-dCF) is a powerful inhibitor of adenosine deaminase (ADA), an enzyme found in high concentrations in lymphoid tissue.	Pentostatin	20-26	adenosine deaminase	Homo sapiens	55-74
7018725-2	1981	2"-deoxycoformycin (2"-dCF) is a powerful inhibitor of adenosine deaminase (ADA), an enzyme found in high concentrations in lymphoid tissue.	Pentostatin	20-26	adenosine deaminase	Homo sapiens	76-79
6785321-5	1981	Thy-ALL blasts, however, appear to be selectively and exquisitely susceptible to inhibition of ADA by the drug deoxycoformycin, which has now been used sucessfully in a number of other wise resistant patients with Thy-ALL to obtain a complete remission.	Pentostatin	111-126	adenosine deaminase	Homo sapiens	95-98
6256482-3	1980	Adenosine deaminase was inactivated by deoxycoformycin prior to stimulation of cyclic AMP accumulation by adenosine or amines.	Pentostatin	39-54	adenosine deaminase	Cavia porcellus	0-19
6967747-1	1980	We have treated a patient with refractory T-cell acute lymphoblastic leukemia with 2"-deoxycoformycin, a potent inhibitor of the enzyme adenosine deaminase.	Pentostatin	83-101	adenosine deaminase	Homo sapiens	136-155
6105339-1	1980	Two patients with relapsed acute lymphoblastic leukaemia of thymic phenotype (Thy-ALL) resistant to all conventional chemotherapy achieved complete remission when treated with 2"-deoxycoformycin, a selectively lymphocytotoxic compound that acts by inhibition of the enzyme adenosine deaminase.	Pentostatin	176-194	adenosine deaminase	Homo sapiens	273-292
6968908-1	1980	An in vivo murine model for immunodeficiency of both B and T cells is produced by continuous intraperitoneal infusion of 2"-deoxycoformycin (DCF), a specific tightly binding inhibitor of adenosine deaminase (ADase; adenosine aminohydrolase, EC 3.5.4.4).	Pentostatin	121-139	adenosine deaminase	Mus musculus	187-206
6968908-1	1980	An in vivo murine model for immunodeficiency of both B and T cells is produced by continuous intraperitoneal infusion of 2"-deoxycoformycin (DCF), a specific tightly binding inhibitor of adenosine deaminase (ADase; adenosine aminohydrolase, EC 3.5.4.4).	Pentostatin	121-139	adenosine deaminase	Mus musculus	208-213
6968908-1	1980	An in vivo murine model for immunodeficiency of both B and T cells is produced by continuous intraperitoneal infusion of 2"-deoxycoformycin (DCF), a specific tightly binding inhibitor of adenosine deaminase (ADase; adenosine aminohydrolase, EC 3.5.4.4).	Pentostatin	141-144	adenosine deaminase	Mus musculus	187-206
6968908-1	1980	An in vivo murine model for immunodeficiency of both B and T cells is produced by continuous intraperitoneal infusion of 2"-deoxycoformycin (DCF), a specific tightly binding inhibitor of adenosine deaminase (ADase; adenosine aminohydrolase, EC 3.5.4.4).	Pentostatin	141-144	adenosine deaminase	Mus musculus	208-213
6968908-2	1980	After DCF infusion, ADase of thymus, spleen, and lymph nodes was inhibited to varying degrees ranging from 57% to 100%.	Pentostatin	6-9	adenosine deaminase	Mus musculus	20-25
6966932-0	1980	Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.	Pentostatin	31-46	adenosine deaminase	Mus musculus	64-83
421226-0	1979	Recovery of 2"-deoxycoformycin-inhibited adenosine deaminase of mouse erythrocytes and leukemia L1210 in vivo.	Pentostatin	12-30	adenosine deaminase	Mus musculus	41-60
6249264-8	1980	Pentostatin (30 microM), a specific inhibitor of adenosine deaminase, completely inhibited hypoxanthine production from exogenous adenosine (55 microM), but did not black CN-induced hypoxanthine production or cause adenosine accumulation in intact cells.	Pentostatin	0-11	adenosine deaminase	Rattus norvegicus	49-68
6970629-1	1980	Deoxycoformycin, a tight-binding inhibitor of the enzyme adenosine deaminase, is a potent lymphocytotoxic agent.	Pentostatin	0-15	adenosine deaminase	Mus musculus	57-76
6970630-0	1980	The clinical pharmacology of the adenosine deaminase inhibitor 2"-deoxycoformycin.	Pentostatin	63-81	adenosine deaminase	Homo sapiens	33-52
6970630-1	1980	2"-deoxycoformycin (2"-dCF; Pentostatin), a stoichiometric inhibitor of mammalian adenosine deaminase (ado deaminase), exhibits immunosuppressive and antilymphocytic activity in animal test systems.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	82-101
6970630-1	1980	2"-deoxycoformycin (2"-dCF; Pentostatin), a stoichiometric inhibitor of mammalian adenosine deaminase (ado deaminase), exhibits immunosuppressive and antilymphocytic activity in animal test systems.	Pentostatin	20-26	adenosine deaminase	Homo sapiens	82-101
6970630-1	1980	2"-deoxycoformycin (2"-dCF; Pentostatin), a stoichiometric inhibitor of mammalian adenosine deaminase (ado deaminase), exhibits immunosuppressive and antilymphocytic activity in animal test systems.	Pentostatin	28-39	adenosine deaminase	Homo sapiens	82-101
455289-0	1979	Effects of 2"-deoxycoformycin infusion on mouse adenosine deaminase.	Pentostatin	11-29	adenosine deaminase	Mus musculus	48-67
454456-0	1979	Enzyme inhibition titration assay for 2"-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats.	Pentostatin	38-56	adenosine deaminase	Canis lupus familiaris	148-167
421226-1	1979	The antibiotic 2"-deoxycoformycin, a potent inhibitor of adenosine deaminase, has potential as a chemotherapeutic agent.	Pentostatin	15-33	adenosine deaminase	Mus musculus	57-76
311477-4	1979	However, in the presence of deoxycoformycin, a potent inhibitor of adenosine deaminase, these macrophages also excreted deoxyadenosine.	Pentostatin	28-43	adenosine deaminase	Mus musculus	67-86
301772-1	1977	The growth of cultured L5178Y cells is inhibited by relatively low concentrations fo deoxyadenosine in the presence of deoxycoformycin, an inhibitor of adenosine deaminase.	Pentostatin	119-134	adenosine deaminase	Mus musculus	152-171
231980-10	1979	The effects of inosine, or adenosine along with an inhibitor of adenosine deaminase (pentostatin) suggest that adenosine acts on the glucose consumption through adenylic nucleotides.	Pentostatin	85-96	adenosine deaminase	Rattus norvegicus	64-83
119038-2	1979	Inhibition was greatly enhanced by an adenosine deaminase inhibitor (2-deoxycoformycin) in concentrations down to 10 ng/ml.	Pentostatin	69-86	adenosine deaminase	Homo sapiens	38-57
218120-5	1979	Pretreatment of the vas deferens with both HNBTG and 2"-deoxycoformycin eliminated the difference in inhibitory potency between adenosine and 2-chloroadenosine.	Pentostatin	53-71	arginine vasopressin	Rattus norvegicus	20-23
750104-2	1978	To examine the in vivo effects of inhibition of this enzyme healthy BDF1 mice were injected intraperitoneally with 2"-deoxycoformycin, a stoichiometric tight-binding inhibitor of adenosine deaminase.	Pentostatin	115-133	adenosine deaminase	Mus musculus	179-198
33507501-4	2021	Introduction of a large number of the amino group, 6.9 mmol g-1, contributes to achieving high adsorption capacities, qm, of 95.6, 124.9, 61.3, and 125.9 mg g-1 for Cd2+, Pb2+, As(V), and DCF, respectively, which is obtained by using the Langmuir model.	Pentostatin	188-191	CD2 molecule	Homo sapiens	165-168
301901-1	1977	The relationship between adenosine deaminase deficiency and immunologic responsiveness was studied in mice treated in vivo with deoxycoformycin to produce very low levels of adenosine deaminase activity in tissues.	Pentostatin	128-143	adenosine deaminase	Mus musculus	25-44
301901-1	1977	The relationship between adenosine deaminase deficiency and immunologic responsiveness was studied in mice treated in vivo with deoxycoformycin to produce very low levels of adenosine deaminase activity in tissues.	Pentostatin	128-143	adenosine deaminase	Mus musculus	174-193
301901-3	1977	Under the conditions used, inhibition of adenosine deaminase by deoxycoformycin had no effect on the viability or responsiveness of either thymocytes or splenic cells.	Pentostatin	64-79	adenosine deaminase	Mus musculus	41-60
191546-4	1977	These same tests were repeated in the presence of a potent inhibitor of adenosine deaminase, R-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo-4,5-d)-(1,3)-diazepin-8-ol (co-vidarabine, co-ara-A).	Pentostatin	191-204	adenosine deaminase	Homo sapiens	72-91
212990-0	1977	Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vira-Atm) for DNA virus replication.	Pentostatin	49-62	ataxia telangiectasia mutated	Mus musculus	139-142
212990-0	1977	Effect of a novel adenosine deaminase inhibitor (co-vidarabine, co-V) upon the antiviral activity in vitro and in vivo of vidarabine (Vira-Atm) for DNA virus replication.	Pentostatin	64-68	ataxia telangiectasia mutated	Mus musculus	139-142
212990-1	1977	A new potent inhibitor of adenosine deaminase (co-vidarabine) was used in combination studies with adenine arabinoside (vidarabine, Vira-ATM) to protect this purine nucleoside from enzymatic deamination to the more weakly active metabolite, hypoxanthine arabinoside.	Pentostatin	47-60	ataxia telangiectasia mutated	Mus musculus	137-140
280146-5	1977	The administration of an inhibitor of adenosine deaminase (Co-vidarabine) in combination with ara-A resulted in an enhanced antiviral response in both infected cell cultures and animals.	Pentostatin	59-72	adenosine deaminase	Mus musculus	38-57
280160-0	1977	Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic disposition of adenine arabinoside (vidarabine).	Pentostatin	37-50	adenosine deaminase	Homo sapiens	14-33
944095-1	1976	2"-Deoxycoformycin (2"-dCF), a potent inhibitor of adenosine deaminase, was tested in combination with 9-beta-D-arabinofuranosyladenine (ara-A) and 9-beta-D-arabinofuranosyladenine 5"-formate for cytotoxic activity against mouse leukemia L1210 in culture.	Pentostatin	0-18	adenosine deaminase	Mus musculus	51-70
944095-1	1976	2"-Deoxycoformycin (2"-dCF), a potent inhibitor of adenosine deaminase, was tested in combination with 9-beta-D-arabinofuranosyladenine (ara-A) and 9-beta-D-arabinofuranosyladenine 5"-formate for cytotoxic activity against mouse leukemia L1210 in culture.	Pentostatin	20-26	adenosine deaminase	Mus musculus	51-70
944095-5	1976	Potentiation of ara-A activity against the relatively insensitive mouse leukemia L1210 was attributed to increased stability of ara-A resulting from 2"-dCF inhibition of adenosine deaminase.	Pentostatin	149-155	adenosine deaminase	Mus musculus	170-189
31332074-6	2019	The results show that dCF antagonizes the effect of MBX-2168 with a >40-fold increase in EC50 at 50 muM dCF (63.1 +- 8.7 muM) when compared with MBX-2168 alone (EC50 = 0.2 +- 0.1 muM).	Pentostatin	107-110	diencephalon/mesencephalon homeobox 1	Homo sapiens	52-55
33948356-8	2021	The administration of naringin and pentostatin, inhibitors for adenosine deaminase (ADA), enzyme responsible for cordycepin degradation, did not show a synergistic effect in MPNST cells treated with cordycepin.	Pentostatin	35-46	adenosine deaminase	Homo sapiens	84-87
33423780-8	2021	It demonstrated the key role of CD4 Th1 specific responses of telomerase and M-MDSC as main prognostic factors for the therapeutic efficacy of DCF.	Pentostatin	143-146	CD4 molecule	Homo sapiens	32-35
33285412-6	2021	Furthermore, all FS interneurons expressing parvalbumin (PV) both in slice cultures and in acute slices from tdTomato-PVCre transgenic mice were also DCF+.	Pentostatin	150-154	parvalbumin	Mus musculus	44-55
32881660-11	2021	CONCLUSION: The serum OPN seems to be a novel significant prognostic and predictive factor in patients with advanced gastric cancer whom treated with DCF regimen.	Pentostatin	150-153	secreted phosphoprotein 1	Homo sapiens	22-25
33476709-0	2021	Pentostatin Antagonizes the Antiviral Activity of MBX-2168 by Inhibiting the Biosynthesis of the Active Compound.	Pentostatin	0-11	diencephalon/mesencephalon homeobox 1	Homo sapiens	50-53
33476709-4	2021	It has been previously demonstrated that co-incubation with pentostatin (dCF), an ADAL-1 inhibitor, antagonizes the anti-viral activity of MBX-2168.	Pentostatin	60-71	diencephalon/mesencephalon homeobox 1	Homo sapiens	139-142
33476709-4	2021	It has been previously demonstrated that co-incubation with pentostatin (dCF), an ADAL-1 inhibitor, antagonizes the anti-viral activity of MBX-2168.	Pentostatin	73-76	diencephalon/mesencephalon homeobox 1	Homo sapiens	139-142
33476709-6	2021	To test this, we examined the effect dCF has on the conversion of MBX-2168 to a triphosphate in HSV-1 and HCMV-infected cells.	Pentostatin	37-40	diencephalon/mesencephalon homeobox 1	Homo sapiens	66-69
33476709-7	2021	Our results demonstrate incubation of MBX-2168 alone or with dCF in HCMV-infected cells resulted in 53.1+-0.7 and 39.4+-1.5 pmol triphosphate/106 cells at 120 hours, respectively.	Pentostatin	61-64	diencephalon/mesencephalon homeobox 1	Homo sapiens	38-41
33476709-8	2021	Incubation of MBX-2168 alone or with dCF in Vero cells resulted in 12.8+-0.1 and 6.7+-0.7 pmol triphosphate/106 cells at 24 hours, respectively.	Pentostatin	37-40	diencephalon/mesencephalon homeobox 1	Homo sapiens	14-17
33476709-10	2021	As expected, incubation with dCF resulted in the accumulation of MBX-2168-MP in both HFF (9.8+-0.9 pmol MBX-2168-MP/106 cells at 120 hours) and Vero cells (4.7+-0.3 pmol MBX-2168-MP/106 cells at 24 hours) while no detectable levels of monophosphate were observed in cultures not incubated with dCF.	Pentostatin	29-32	diencephalon/mesencephalon homeobox 1	Homo sapiens	65-68
33476709-10	2021	As expected, incubation with dCF resulted in the accumulation of MBX-2168-MP in both HFF (9.8+-0.9 pmol MBX-2168-MP/106 cells at 120 hours) and Vero cells (4.7+-0.3 pmol MBX-2168-MP/106 cells at 24 hours) while no detectable levels of monophosphate were observed in cultures not incubated with dCF.	Pentostatin	29-32	diencephalon/mesencephalon homeobox 1	Homo sapiens	104-107
33476709-10	2021	As expected, incubation with dCF resulted in the accumulation of MBX-2168-MP in both HFF (9.8+-0.9 pmol MBX-2168-MP/106 cells at 120 hours) and Vero cells (4.7+-0.3 pmol MBX-2168-MP/106 cells at 24 hours) while no detectable levels of monophosphate were observed in cultures not incubated with dCF.	Pentostatin	29-32	diencephalon/mesencephalon homeobox 1	Homo sapiens	104-107
33476709-11	2021	We conclude that dCF antagonizes the anti-viral effect of MBX-2168 by inhibiting the production of triphosphate, the active compound.	Pentostatin	17-20	diencephalon/mesencephalon homeobox 1	Homo sapiens	58-61
32782608-10	2020	Among patients who underwent neoadjuvant DCF therapy, the RBX1 high expression group had a significantly lower OS rate compared with that of the RBX1-low group (P<0.001).	Pentostatin	41-44	ring-box 1	Homo sapiens	58-62
31332074-6	2019	The results show that dCF antagonizes the effect of MBX-2168 with a &gt;40-fold increase in EC50 at 50 muM dCF (63.1 +- 8.7 muM) when compared with MBX-2168 alone (EC50 = 0.2 +- 0.1 muM).	Pentostatin	22-25	diencephalon/mesencephalon homeobox 1	Homo sapiens	52-55
31551768-7	2019	The reactive oxygen species levels induced by Fe(PIP)3SO4 were measured by 2"-deoxycoformycin (DCF) probe; ABTS assay was utilized to examine the radical scavenge capacity of Fe(PIP)3SO4.	Pentostatin	75-93	prolactin induced protein	Mus musculus	49-52
31551768-7	2019	The reactive oxygen species levels induced by Fe(PIP)3SO4 were measured by 2"-deoxycoformycin (DCF) probe; ABTS assay was utilized to examine the radical scavenge capacity of Fe(PIP)3SO4.	Pentostatin	95-98	prolactin induced protein	Mus musculus	49-52
29910179-3	2018	Here we report the use of CD19-targeted CAR T cells incorporating the intracellular signaling domain of CD28 (19-28z) as a consolidative therapy in 8 patients with residual CLL following first-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab.	Pentostatin	222-233	CD19 molecule	Homo sapiens	26-30
31262713-7	2019	Antioxidative function of FAM129B is analyzed by measuring ROS levels with DCF/flow cytometry, Nrf2 activation using luciferase reporter assay and determination of downstream gene expression by qPCR and wester blotting.	Pentostatin	75-78	niban apoptosis regulator 2	Homo sapiens	26-33
29910179-3	2018	Here we report the use of CD19-targeted CAR T cells incorporating the intracellular signaling domain of CD28 (19-28z) as a consolidative therapy in 8 patients with residual CLL following first-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab.	Pentostatin	222-233	CD28 molecule	Homo sapiens	104-108
28697486-9	2017	Ts65Dn myofibers exhibited a significant decrease in basal DCF emissions (p &lt; 0.05) that was associated with an approximate 3-fold increase in SOD1 (p &lt; 0.05).	Pentostatin	59-62	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	0-6
29051060-7	2017	However, the 5"-nucleotidase activity decreased significantly in infected untreated animals and the same occurred in infected and treated animals with deoxycoformycin and 3"-deoxyadenosine.	Pentostatin	151-166	5' nucleotidase, ecto	Mus musculus	13-28
29051060-8	2017	However, treatment with deoxycoformycin associated with 3"-deoxyadenosine preventing them from decreasing the 5"-nucleotidase activity.	Pentostatin	24-39	5' nucleotidase, ecto	Mus musculus	110-125
28697486-12	2017	In summary, myofibers from Ts65Dn mice exhibited decreased basal DCF emissions that were coupled with elevated protein expression of SOD1.	Pentostatin	65-68	reciprocal translocation, Chr 16, cytogenetic band C3-4; and Chr 17, cytogenetic band A2, Davisson 65	Mus musculus	27-33
28461775-8	2017	Our results showed that PM10 enhanced reactive oxygen species signal by measuring DCF fluorescence and the DCF signal attenuated by both TRPM2 blockers CLZ and ACA.	Pentostatin	107-110	transient receptor potential cation channel subfamily M member 2	Homo sapiens	137-142
28554861-4	2017	Abeta1-40-induced ROS production and p53 expression were increased as determined by DCF-derived fluorescence using flow cytometry and Western blotting and reduced in response to galantamine pretreatment.	Pentostatin	84-87	tumor protein p53	Homo sapiens	37-40
27217381-8	2017	ECoG depression was also shortened by focal application of exogenous adenosine deaminase (ADA; 100 U/mL), and conversely, was prolonged 50% by the non-competitive ADA inhibitor deoxycoformycin (DCF; 100 microM).	Pentostatin	177-192	adenosine deaminase	Mus musculus	90-93
27217381-8	2017	ECoG depression was also shortened by focal application of exogenous adenosine deaminase (ADA; 100 U/mL), and conversely, was prolonged 50% by the non-competitive ADA inhibitor deoxycoformycin (DCF; 100 microM).	Pentostatin	177-192	adenosine deaminase	Mus musculus	163-166
27217381-8	2017	ECoG depression was also shortened by focal application of exogenous adenosine deaminase (ADA; 100 U/mL), and conversely, was prolonged 50% by the non-competitive ADA inhibitor deoxycoformycin (DCF; 100 microM).	Pentostatin	194-197	adenosine deaminase	Mus musculus	90-93
28513806-7	2016	The effect of eADA inhibition on atherosclerosis progression was studied by a 2-month deoxycoformycin treatment of ApoE-/-LDLR-/- mice.	Pentostatin	86-101	apolipoprotein E	Mus musculus	115-119
28425270-9	2017	Furthermore, a decrease in VEGFA by 25% from the pretreatment level was also found as a prognostic factor for OS independent of response to DCF regimen.	Pentostatin	140-143	vascular endothelial growth factor A	Homo sapiens	27-32
27965178-6	2017	The obtained results showed that all of the studied compounds in a wide range of concentrations (1 nM-100 muM) increased DCF fluorescence which suggests a stimulation of ROS production.	Pentostatin	121-124	latexin	Homo sapiens	106-109
26513708-3	2016	Glucose oxidase (GOx)-induced oxidative stress led to mitochondrial dysfunction, decreased intracellular ATP content, and, at higher concentrations, increased intracellular oxidant formation (estimated by the fluorescent probe 2, 7-dichlorofluorescein, DCF) and promoted necrosis (estimated by the measurement of lactate dehydrogenase release into the medium) of the NRK cells in vitro.	Pentostatin	253-256	hydroxyacid oxidase 1	Homo sapiens	0-15
28513806-12	2016	Deoxycoformycin treatment attenuated plaque development in aortic root and brachiocephalic artery of ApoE-/-LDLR-/- mice, suppressed vascular inflammation and improved endothelial function.	Pentostatin	0-15	apolipoprotein E	Mus musculus	101-105
28513806-12	2016	Deoxycoformycin treatment attenuated plaque development in aortic root and brachiocephalic artery of ApoE-/-LDLR-/- mice, suppressed vascular inflammation and improved endothelial function.	Pentostatin	0-15	low density lipoprotein receptor	Mus musculus	108-112
26659614-1	2016	The treatment with deoxycoformycin, a strong adenosine deaminase inhibitor, in combination with deoxyadenosine, causes apoptotic cell death of two human neuroblastoma cell lines, SH-SY5Y and LAN5.	Pentostatin	19-34	adenosine deaminase	Homo sapiens	45-64
26513708-3	2016	Glucose oxidase (GOx)-induced oxidative stress led to mitochondrial dysfunction, decreased intracellular ATP content, and, at higher concentrations, increased intracellular oxidant formation (estimated by the fluorescent probe 2, 7-dichlorofluorescein, DCF) and promoted necrosis (estimated by the measurement of lactate dehydrogenase release into the medium) of the NRK cells in vitro.	Pentostatin	253-256	hydroxyacid oxidase 1	Homo sapiens	17-20
26348080-9	2015	Interestingly ROS level (using DCF detection technique) and lipid peroxidation ratio were increased in cells stimulated by visfatin/eNampt in concentration of 250 ng/ml along with the decreased activity of selected antioxidant enzymes when compared to remaining study groups, including control.	Pentostatin	31-34	nicotinamide phosphoribosyltransferase	Homo sapiens	123-131
25462277-4	2015	The compound 36 had better cytotoxic activities (IC50 &lt;= 1 muM) than the nucleobase 5-FU and nucleosides fludarabine, cladribine, and pentostatine on Huh7 cells.	Pentostatin	137-149	MIR7-3 host gene	Homo sapiens	153-157
24797340-10	2014	The results also indicated that mutation levels in blood and bone marrow are not systematically different, and next-generation sequencing-based STAT3 mutation analysis represents a sensitive method for monitoring residual disease as demonstrated in a patient receiving pentostatin.	Pentostatin	269-280	signal transducer and activator of transcription 3	Homo sapiens	144-149
25447764-5	2015	We have previously demonstrated that the combination of deoxycoformycin, a strong adenosine deaminase inhibitor, and deoxyadenosine is toxic for a human astrocytoma cell line.	Pentostatin	56-71	adenosine deaminase	Homo sapiens	82-101
25447764-8	2015	In this work we demonstrate that after 8 h of incubation with deoxyadenosine and deoxycoformycin, caspase-8 is activated, mitochondrial mass increases and mitochondrial reactive oxygen species decrease.	Pentostatin	81-96	caspase 8	Homo sapiens	98-107
25447764-9	2015	The addition of baicalein to the incubation medium reduces cell death and caspase-3 activity induced by deoxycoformycin and deoxyadenosine in combination.	Pentostatin	104-119	caspase 3	Homo sapiens	74-83
25233630-12	2014	The ROS and MDA levels of three different doses FGF-21 treatment group reduced significantly than that of the model group [(5.58 +/- 1.07), (7.78 +/- 1.92), (9.03 +/- 1.77) vs (12.75 +/- 2.02) pmol (DCF) x min(-1) x mg(-1), P &lt; 0.01 or P &lt; 0.05], [(2.92 +/- 0.71), (4.21 +/- 0.81), (4.41 +/- 0.97) vs (5.62 +/- 0.63) nmol x mg(-1) (protein), P &lt; 0.01].	Pentostatin	199-202	fibroblast growth factor 21	Mus musculus	48-54
23948373-7	2013	The levels of DCF and MitoSOX Red, which are indicative of the oxidative stress, were significantly higher in the B4 cells in basal conditions and after insulin treatment.	Pentostatin	14-17	insulin	Homo sapiens	153-160
24606952-8	2014	Significantly lower LDH levels (p &lt; 0.05) were observed as were lower DCF fluorescence intensity (p &lt; 0.05) in FABP1 cDNA transfected cells compared to vector transfected cells.	Pentostatin	73-76	fatty acid binding protein 1	Homo sapiens	117-122
25057084-1	2014	OBJECTIVE: To investigate the efficacy and adverse effect of DCF regimen with subsequent S-1 maintenance chemotherapy in patients with advanced gastric cancer (AGC).	Pentostatin	61-64	proteasome 26S subunit, non-ATPase 1	Homo sapiens	89-92
25057084-7	2014	CONCLUSION: S-1 maintenance chemotherapy, with a tolerable toxicity profile, can improve the RR, DCR and median time to progression in AGC patients who respond to DCF regimen, but its efficacy still awaits further evaluation.	Pentostatin	163-166	proteasome 26S subunit, non-ATPase 1	Homo sapiens	12-15
23361035-1	2013	The aim of this study was to evaluate the anti-trypanosomal effect of treatment with 3"-deoxyadenosine (cordycepin) combined with deoxycoformycin (pentostatin: inhibitor of the enzyme adenosine deaminase) in vitro by using mice experimentally infected with Trypanosoma evansi.	Pentostatin	130-145	adenosine deaminase	Mus musculus	184-203
23968883-8	2013	We observed that both cadmium and zinc permeate hTRPV5 in ion imaging experiments using Fura-2 or Newport Green DCF.	Pentostatin	112-115	transient receptor potential cation channel subfamily V member 5	Homo sapiens	48-54
23632090-0	2013	Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting.	Pentostatin	30-41	CD4 molecule	Homo sapiens	18-21
23933282-0	2013	Influence of treatment with 3"-deoxyadenosine associated deoxycoformycin on hematological parameters and activity of adenosine deaminase in infected mice with Trypanosoma evansi.	Pentostatin	57-72	adenosine deaminase	Mus musculus	117-136
23933282-1	2013	This study aimed to verify the effect of 3"-deoxyadenosine and deoxycoformycin on hematologic parameters and adenosine deaminase (ADA) activity in plasma and brain of mice infected with Trypanosoma evansi.	Pentostatin	63-78	adenosine deaminase	Mus musculus	109-128
23933282-10	2013	The deoxycoformycin was able to inhibit the ADA activity of parasite thus it may be one of the mechanisms of efficacy of this treatment.	Pentostatin	4-19	adenosine deaminase	Mus musculus	44-47
23828702-11	2013	CONCLUSION: High TUBB3 mRNA expression is correlated with resistance to DCF regimen chemotherapy.	Pentostatin	72-75	tubulin beta 3 class III	Homo sapiens	17-22
23361035-1	2013	The aim of this study was to evaluate the anti-trypanosomal effect of treatment with 3"-deoxyadenosine (cordycepin) combined with deoxycoformycin (pentostatin: inhibitor of the enzyme adenosine deaminase) in vitro by using mice experimentally infected with Trypanosoma evansi.	Pentostatin	147-158	adenosine deaminase	Mus musculus	184-203
23603888-1	2013	Using a newly developed near-infrared (NIR) dye that fluoresces at two different wavelengths (dichromic fluorescence, DCF), we discovered a new fluorescent substrate for Akt, also known as protein kinase B, and a method to quantitatively report this enzyme"s activity in real time.	Pentostatin	118-121	AKT serine/threonine kinase 1	Homo sapiens	170-173
23774147-8	2013	CONCLUSION: The gene polymorphisms of GSTP1 G/G, XRCC1 A/A, and 5,10-MTHFR T/T have clinical value for predicting the response to the DCF regimen for advanced gastric cancer.	Pentostatin	134-137	glutathione S-transferase pi 1	Homo sapiens	38-43
23774147-8	2013	CONCLUSION: The gene polymorphisms of GSTP1 G/G, XRCC1 A/A, and 5,10-MTHFR T/T have clinical value for predicting the response to the DCF regimen for advanced gastric cancer.	Pentostatin	134-137	X-ray repair cross complementing 1	Homo sapiens	49-54
23774147-8	2013	CONCLUSION: The gene polymorphisms of GSTP1 G/G, XRCC1 A/A, and 5,10-MTHFR T/T have clinical value for predicting the response to the DCF regimen for advanced gastric cancer.	Pentostatin	134-137	methylenetetrahydrofolate reductase	Homo sapiens	69-74
23603888-2	2013	Upon insulin activation of cellular Akt, the enzyme multi-phosphorylated a single serine residue of a diserine DCF substrate in a time-dependent manner, culminating in monophospho- to triphospho-serine products.	Pentostatin	111-114	AKT serine/threonine kinase 1	Homo sapiens	36-39
23603888-4	2013	The DCF mechanism provides unparalleled potential to assess the stimulation, sustainability, and reversibility of Akt activation longitudinally.	Pentostatin	4-7	AKT serine/threonine kinase 1	Homo sapiens	114-117
22268651-10	2012	EZS inhibited the production of TNF-alpha-induced formation of DCF-sensitive intracellular reactive oxygen species (ROS).	Pentostatin	63-66	tumor necrosis factor	Homo sapiens	32-41
22047938-16	2012	The use of 2"-deoxycoformycin and other targeted therapies, such as alemtuzumab, anti-gammadelta TCR monoclonal antibodies, and anti-CD44 therapy, have shown promising results in anecdotal reports.	Pentostatin	11-29	CD44 molecule (Indian blood group)	Homo sapiens	133-137
22086824-3	2012	PrB suppressed H2O2-initiated oxidation (DCF assay) and cell death (MTT assay) in SH-SY5Y cells.	Pentostatin	41-44	RB transcriptional corepressor 1	Homo sapiens	0-3
22353632-3	2012	We have mimicked an adenosine deaminase-deficient situation by incubating a human astrocytoma cell line in the presence of deoxycoformycin, a strong adenosine deaminase inhibitor, and deoxyadenosine, which accumulates in vivo when the enzyme is deficient, and have monitored the effect of the combination on cell viability, mitochondrial functions, and other metabolic features.	Pentostatin	123-138	adenosine deaminase	Homo sapiens	20-39
22353632-3	2012	We have mimicked an adenosine deaminase-deficient situation by incubating a human astrocytoma cell line in the presence of deoxycoformycin, a strong adenosine deaminase inhibitor, and deoxyadenosine, which accumulates in vivo when the enzyme is deficient, and have monitored the effect of the combination on cell viability, mitochondrial functions, and other metabolic features.	Pentostatin	123-138	adenosine deaminase	Homo sapiens	149-168
22273151-5	2012	DCF inhibited constitutive STAT3 activation through blocking upstream Janus-like kinase 2 and c-Src.	Pentostatin	0-3	signal transducer and activator of transcription 3	Homo sapiens	27-32
22348473-5	2012	In protoplasts of Arabidopsis mutant vtc2-2 with disturbed biosynthesis of ascorbate, the rate of increase in DCF fluorescence intensity in chloroplasts was considerably higher than in protoplasts of the wild type plant.	Pentostatin	110-113	GDP-L-galactose phosphorylase 1	Arabidopsis thaliana	37-41
22273151-5	2012	DCF inhibited constitutive STAT3 activation through blocking upstream Janus-like kinase 2 and c-Src.	Pentostatin	0-3	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	94-99
22273151-8	2012	Nobiletin, a major active constituent of DCF, could induce apoptosis via the suppression of constitutive STAT3 activation.	Pentostatin	41-44	signal transducer and activator of transcription 3	Homo sapiens	105-110
22273151-9	2012	Overall, our results indicate that the anti-inflammatory and anticancer activities previously assigned to DCF may be mediated partially through the suppression of the STAT3 signaling.	Pentostatin	106-109	signal transducer and activator of transcription 3	Homo sapiens	167-172
22916248-13	2012	Silencing PRDX2 in moDCs by means of siRNA significantly increased CM-DCF fluorescence and cell death upon tert-BHP-stimulation.	Pentostatin	70-73	peroxiredoxin 2	Homo sapiens	10-15
21463108-8	2011	These additional modes of action produce further DNA breaks in CdA-treated cells and explain the more potent activity of CdA compared to dCF and the greater myelosuppression with this agent.	Pentostatin	137-140	cytidine deaminase	Homo sapiens	63-66
20018174-4	2010	Intracellular ROS was measured in THBP transfected cells using DCF fluorescence.	Pentostatin	63-66	crystallin mu	Homo sapiens	34-38
20228181-10	2010	We further demonstrated that elevation of cellular adenosine by inhibition of adenosine deaminase with Pentostatin significantly enhanced endothelial basal barrier function, an effect that was also associated with enhanced Rac1 GTPase activity and with increased focal adhesion complexes and adherens junctions.	Pentostatin	103-114	Rac family small GTPase 1	Homo sapiens	223-227
21463108-3	2011	dCF is a potent inhibitor of adenosine deaminase (ADA), and treatment results in the accumulation of deoxyadenosine (dAdo) and adenosine (Ado) in the plasma.	Pentostatin	0-3	adenosine deaminase	Homo sapiens	29-48
21463108-3	2011	dCF is a potent inhibitor of adenosine deaminase (ADA), and treatment results in the accumulation of deoxyadenosine (dAdo) and adenosine (Ado) in the plasma.	Pentostatin	0-3	adenosine deaminase	Homo sapiens	50-53
24278549-7	2011	The activities of CAT and GST were lowered in the DCF group than the DC group by 26% (p &lt; 0.05) and 7.6%, respectively.	Pentostatin	50-53	catalase	Mus musculus	18-21
19728741-14	2009	Compared to malarial ADA complexes with adenosine or deoxycoformycin, 5"-methylthioribosyl groups are rotated 130 degrees .	Pentostatin	53-68	adenosine deaminase	Homo sapiens	21-24
21614175-7	2010	DCF assay experiments showed that the reactive oxygen species (ROS) levels increased and mitochondrial DNA (mtDNA) copy number decreased in loss-of-function lin-4 mutants.	Pentostatin	0-3	lin-4	Caenorhabditis elegans	157-162
20001428-6	2010	Furthermore, the "gold standards" of HCL therapy - cladribine and pentostatin - are associated with profound and prolonged suppression of the CD4(+) T-lymphocyte counts, often in excess of 2 - 3 years.	Pentostatin	66-77	CD4 molecule	Homo sapiens	142-145
19409874-2	2009	Ang II (1nM) stimulated DCF fluorescence, an intranuclear indicator of reactive oxygen species (ROS), while the AT1R antagonist losartan or the NADPH oxidase (NOX) inhibitor DPI abolished the increase in ROS.	Pentostatin	24-27	angiogenin	Homo sapiens	0-3
19375500-5	2009	Our data demonstrate that Ox-PAPC increases reactive oxygen species formation in HAECs as seen by DCF fluorescence.	Pentostatin	98-101	protocadherin 8	Homo sapiens	29-33
17659340-2	2007	We measured TCL-1 protein in CLL cells from 51 patients who then received pentostatin, cyclophosphamide, and rituximab.	Pentostatin	74-85	TCL1 family AKT coactivator A	Homo sapiens	12-17
19957532-9	2009	The relative intensity of DCF fluorescence was 8.9 +/- 0.7 for slaty melanocytes versus 8.9 +/- 2.5 for melan-a melanocytes prior to UVA irradiation, but an abrupt ROS production was merely observed in slaty MCs (18.0 +/- 0.3) other than in melan-a MCs (13.6 +/- 0.3) after UVA exposure.	Pentostatin	26-29	dopachrome tautomerase	Mus musculus	63-68
19957532-9	2009	The relative intensity of DCF fluorescence was 8.9 +/- 0.7 for slaty melanocytes versus 8.9 +/- 2.5 for melan-a melanocytes prior to UVA irradiation, but an abrupt ROS production was merely observed in slaty MCs (18.0 +/- 0.3) other than in melan-a MCs (13.6 +/- 0.3) after UVA exposure.	Pentostatin	26-29	dopachrome tautomerase	Mus musculus	202-207
18340641-0	2008	Therapeutic benefit of pentostatin in severe IL-10-/- colitis.	Pentostatin	23-34	interleukin 10	Mus musculus	45-50
18340641-11	2008	Analysis of mucosal lymphocyte subsets suggested pentostatin reduced numbers of effector CD4+ CD69+ T cells, while sparing CD4+ CD62L+ T cells.	Pentostatin	49-60	CD4 antigen	Mus musculus	89-92
19008456-0	2009	Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab.	Pentostatin	106-117	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	0-5
19008456-4	2009	We investigated Mcl-1 protein expression prospectively as part of a phase 2 study evaluating the efficacy of pentostatin, cyclophosphamide, and rituximab in patients with untreated CLL.	Pentostatin	109-120	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	16-21
18602399-7	2008	We now report crystal structures of Plasmodium vivax ADA in complex with adenosine, guanosine, and the picomolar inhibitor 2"-deoxycoformycin.	Pentostatin	123-141	adenosine deaminase	Homo sapiens	53-56
18721115-3	2008	OBJECTIVE: To identify the role of pentostatin, a specific inhibitor of adenosine deaminase (ADA), in the treatment of CLL.	Pentostatin	35-46	adenosine deaminase	Homo sapiens	72-91
18721115-3	2008	OBJECTIVE: To identify the role of pentostatin, a specific inhibitor of adenosine deaminase (ADA), in the treatment of CLL.	Pentostatin	35-46	adenosine deaminase	Homo sapiens	93-96
17339480-5	2007	Catalase transgenic mice had 8-fold increases in catalase activity in lung tissue, and had lowered DCF oxidation in tracheal epithelial cells, compared with C57BL/6 controls.	Pentostatin	99-102	catalase	Mus musculus	0-8
17958324-9	2007	In addition, DPI significantly inhibited the ET-1- induced ROS production when ROS was measured as a function of DCF fluorescence.	Pentostatin	113-116	endothelin 1	Homo sapiens	45-49
16670267-7	2006	Functional studies of murine hypoxia revealed inhibition of ADA with deoxycoformycin (dCF) enhances protective responses mediated by adenosine (vascular leak and neutrophil accumulation).	Pentostatin	69-84	adenosine deaminase	Mus musculus	60-63
17097637-4	2007	These effects were potentiated by co-incubation with homocysteine or adenosine deaminase inhibitor, pentostatin, and were mimicked by inhibition of AdoHcy hydrolase by adenosine-2",3"-dialdehyde (Adox).	Pentostatin	100-111	adenosine deaminase	Homo sapiens	69-88
17522789-5	2007	RESULTS: Primary findings: percentage of time per patient with temperature&gt;38 degrees C was significantly lower (P&lt;0.0001) in the DCF group, 4% (0-22%), vs. 34% (8-56%) in CTRL group.	Pentostatin	136-139	chymotrypsin like	Homo sapiens	178-182
17522789-8	2007	However, if ICP pre randomization was &lt;25 mmHg, CTRL suffered a worst ICP (24+/-11 vs. 16+/-7 P=0.01), MAP (89+/-10 vs. 104+/-10 P=0.01) and CPP (75+/-10 vs. 94+/-17 P=0.01) compared to DCF.	Pentostatin	189-192	chymotrypsin like	Homo sapiens	51-55
16670267-7	2006	Functional studies of murine hypoxia revealed inhibition of ADA with deoxycoformycin (dCF) enhances protective responses mediated by adenosine (vascular leak and neutrophil accumulation).	Pentostatin	86-89	adenosine deaminase	Mus musculus	60-63
16603734-3	2006	We now report the genetic confirmation of this hypothesis through the construction of a conditional delta hgprt/delta xprt mutant strain that exhibits an absolute requirement for 2"-deoxycoformycin, an inhibitor of the leishmanial adenine aminohydrolase enzyme, and either adenine or adenosine as a source of purine.	Pentostatin	179-197	hypoxanthine guanine phosphoribosyl transferase	Mus musculus	106-111
16787924-7	2006	Imaging ROS with the H2O2-sensitive dye DCF revealed that ATP induces generation of peroxide in astrocytes via activation of P2Y1 receptors coupled to intracellular calcium rise.	Pentostatin	40-43	purinergic receptor P2Y1	Homo sapiens	125-129
16863999-9	2006	The midpoint reduction potential of the couple DCF,H(+)/DCFH() is approximately -0.75 V vs. NHE at pH 7.4; DCF is unlikely to be reduced rapidly by common flavoprotein reductases.	Pentostatin	47-50	solute carrier family 9 member C1	Homo sapiens	92-95
16863999-9	2006	The midpoint reduction potential of the couple DCF,H(+)/DCFH() is approximately -0.75 V vs. NHE at pH 7.4; DCF is unlikely to be reduced rapidly by common flavoprotein reductases.	Pentostatin	56-59	solute carrier family 9 member C1	Homo sapiens	92-95
16603734-3	2006	We now report the genetic confirmation of this hypothesis through the construction of a conditional delta hgprt/delta xprt mutant strain that exhibits an absolute requirement for 2"-deoxycoformycin, an inhibitor of the leishmanial adenine aminohydrolase enzyme, and either adenine or adenosine as a source of purine.	Pentostatin	179-197	xanthine phosphoribosyltransferase	Leishmania donovani	118-122
16511360-8	2006	Moreover, DCF fluorescence was intensified in CuZnSOD-transfected HaCaT and RAW 264.7 cells.	Pentostatin	10-13	superoxide dismutase 1	Homo sapiens	46-53
16549110-2	2006	Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism.	Pentostatin	12-23	adenosine deaminase	Homo sapiens	61-80
16549110-2	2006	Among them, pentostatin is also a tight binding inhibitor of adenosine deaminase (ADA), a key enzyme of purine metabolism.	Pentostatin	12-23	adenosine deaminase	Homo sapiens	82-85
16549110-4	2006	Early clinical trials with pentostatin used high doses for acute lymphoblastic leukemias, which were characterized by high levels of ADA.	Pentostatin	27-38	adenosine deaminase	Homo sapiens	133-136
16175609-12	2005	Transfected cells showed decreased DCF fluorescence intensity under oxidative stress (H2O2 and hypoxia/reoxygenation) conditions versus control in inverse proportion to the level of L-FABP expression.	Pentostatin	35-38	fatty acid binding protein 1	Homo sapiens	182-188
16542004-2	2006	This in vivo study explores this prodrug conversion in rats and inhibition by a potent adenosine deaminase inhibitor, 2"-deoxycoformycin.	Pentostatin	118-136	adenosine deaminase	Rattus norvegicus	87-106
15837980-3	2005	Pentostatin, a potent inhibitor of adenosine deaminase, induces lymphocyte apoptosis and may be useful in the treatment of this condition.	Pentostatin	0-11	adenosine deaminase	Homo sapiens	35-54
16123445-7	2005	GLUT1-overexpressing cells had a 80% increase in DCF fluorescence and increased lipid peroxidation, as well as increased JNK phosphorylation.	Pentostatin	49-52	solute carrier family 2 member 1	Rattus norvegicus	0-5
15820256-7	2005	This correlated with a decrease in TNF-alpha- or angiotensin-II-induced ROS production assayed by DCF fluorescence.	Pentostatin	98-101	tumor necrosis factor	Homo sapiens	35-44
15752710-4	2005	Here, we show that deoxyadenosine itself is also a potent activator of dCK if its deamination was prevented by the adenosine deaminase inhibitor deoxycoformycin.	Pentostatin	145-160	Calcium/calmodulin-dependent protein kinase II	Drosophila melanogaster	71-74
15752710-4	2005	Here, we show that deoxyadenosine itself is also a potent activator of dCK if its deamination was prevented by the adenosine deaminase inhibitor deoxycoformycin.	Pentostatin	145-160	adenosine deaminase	Homo sapiens	115-134
15820256-7	2005	This correlated with a decrease in TNF-alpha- or angiotensin-II-induced ROS production assayed by DCF fluorescence.	Pentostatin	98-101	angiotensinogen	Homo sapiens	49-63
12883733-0	2003	Pentostatin in T-non-Hodgkin"s lymphomas: efficacy and effect on CD26+ T lymphocytes.	Pentostatin	0-11	dipeptidyl peptidase 4	Homo sapiens	65-69
15665518-3	2005	The effects on p38 MAPK and ROS production were evaluated by immunoblots and analysis of DCF-DA fluorescence, respectively.	Pentostatin	89-92	mitogen-activated protein kinase 14	Homo sapiens	15-18
15135110-9	2004	The deamination of CdA was completely inhibited by deoxycoformycin, which clearly demonstrates that CdA is a substrate for adenosine deaminase.	Pentostatin	51-66	adenosine deaminase	Homo sapiens	123-142
14760072-6	2004	This latter point was confirmed in vivo, in a patient affected by CD26(-) T-cell receptor gammadelta(+) hepatosplenic gammadelta(+) T-cell lymphomas treated on a compassionate basis with dCF.	Pentostatin	187-190	dipeptidyl peptidase 4	Homo sapiens	66-133
14760072-7	2004	The inverse correlation between CD26 expression and sensitivity to dCF was also demonstrated in a lymphoblastic lymphoma case in which CD26 was expressed on circulating blasts at relapse but not at diagnosis, as well as in two H9 T-cell clones expressing or not expressing CD26 mRNA and protein.	Pentostatin	67-70	dipeptidyl peptidase 4	Homo sapiens	32-36
14760072-7	2004	The inverse correlation between CD26 expression and sensitivity to dCF was also demonstrated in a lymphoblastic lymphoma case in which CD26 was expressed on circulating blasts at relapse but not at diagnosis, as well as in two H9 T-cell clones expressing or not expressing CD26 mRNA and protein.	Pentostatin	67-70	dipeptidyl peptidase 4	Homo sapiens	135-139
14760072-7	2004	The inverse correlation between CD26 expression and sensitivity to dCF was also demonstrated in a lymphoblastic lymphoma case in which CD26 was expressed on circulating blasts at relapse but not at diagnosis, as well as in two H9 T-cell clones expressing or not expressing CD26 mRNA and protein.	Pentostatin	67-70	dipeptidyl peptidase 4	Homo sapiens	135-139
14760072-8	2004	CONCLUSIONS: This study corroborates the notion of CD26 as a marker of poor prognosis for T-cell malignancies and delineates a role for CD26 as a predictor of poor response to dCF.	Pentostatin	176-179	dipeptidyl peptidase 4	Homo sapiens	136-140
15763950-7	2004	Inhibition of the NADPH oxidase using gp91ds-tat prevented the Ang II-induced increase in DCF fluorescence, without affecting cells loaded with H2-calcein.	Pentostatin	90-93	angiotensinogen	Homo sapiens	63-69
14699015-5	2004	Preincubation of VSMCs with IL-6 resulted in an enhanced angiotensin II-induced production of reactive oxygen species, as assessed by DCF fluorescence laser microscopy.	Pentostatin	134-137	interleukin 6	Mus musculus	28-32
14760072-0	2004	CD26 expression correlates with a reduced sensitivity to 2"-deoxycoformycin-induced growth inhibition and apoptosis in T-cell leukemia/lymphomas.	Pentostatin	57-75	dipeptidyl peptidase 4	Homo sapiens	0-4
14760072-1	2004	PURPOSE AND EXPERIMENTAL DESIGN: dCF (2"-deoxycoformycin) is a potent inhibitor of ADA (adenosine deaminase), an enzyme regulating intra- and extracellular concentrations of purine metabolites.	Pentostatin	33-36	adenosine deaminase	Homo sapiens	83-86
14760072-1	2004	PURPOSE AND EXPERIMENTAL DESIGN: dCF (2"-deoxycoformycin) is a potent inhibitor of ADA (adenosine deaminase), an enzyme regulating intra- and extracellular concentrations of purine metabolites.	Pentostatin	33-36	adenosine deaminase	Homo sapiens	88-107
14760072-1	2004	PURPOSE AND EXPERIMENTAL DESIGN: dCF (2"-deoxycoformycin) is a potent inhibitor of ADA (adenosine deaminase), an enzyme regulating intra- and extracellular concentrations of purine metabolites.	Pentostatin	38-56	adenosine deaminase	Homo sapiens	83-86
14760072-1	2004	PURPOSE AND EXPERIMENTAL DESIGN: dCF (2"-deoxycoformycin) is a potent inhibitor of ADA (adenosine deaminase), an enzyme regulating intra- and extracellular concentrations of purine metabolites.	Pentostatin	38-56	adenosine deaminase	Homo sapiens	88-107
14760072-3	2004	Once the surface expression of CD26 and ADA in a panel of cell lines and primary samples of T-cell leukemia/lymphoma was defined, we correlated this expression with the antiproliferative and apoptotic effect of dCF.	Pentostatin	211-214	dipeptidyl peptidase 4	Homo sapiens	31-35
14760072-3	2004	Once the surface expression of CD26 and ADA in a panel of cell lines and primary samples of T-cell leukemia/lymphoma was defined, we correlated this expression with the antiproliferative and apoptotic effect of dCF.	Pentostatin	211-214	adenosine deaminase	Homo sapiens	40-43
14760072-4	2004	RESULTS: Surface expression of CD26 inversely correlated with the capability of dCF to inhibit cell growth and induce apoptosis both in T-cell lines and primary samples of T-cell malignancies.	Pentostatin	80-83	dipeptidyl peptidase 4	Homo sapiens	31-35
14630704-5	2004	The ability of ecto-ADA to inhibit the cAMP response was demonstrated by treatment with the specific ADA inhibitor 2"-deoxycoformycin.	Pentostatin	115-133	adenosine deaminase	Homo sapiens	15-23
14630704-5	2004	The ability of ecto-ADA to inhibit the cAMP response was demonstrated by treatment with the specific ADA inhibitor 2"-deoxycoformycin.	Pentostatin	115-133	adenosine deaminase	Homo sapiens	20-23
12883733-4	2003	We also examined the lymphopenic effect of pentostatin on CD26+ T lymphocytes.	Pentostatin	43-54	dipeptidyl peptidase 4	Homo sapiens	58-62
12883733-11	2003	Pentostatin also specifically depleted CD26+ rather than CD26- T lymphocytes, potentially associated with immunosuppression.	Pentostatin	0-11	dipeptidyl peptidase 4	Homo sapiens	39-43
12883733-11	2003	Pentostatin also specifically depleted CD26+ rather than CD26- T lymphocytes, potentially associated with immunosuppression.	Pentostatin	0-11	dipeptidyl peptidase 4	Homo sapiens	57-61
12883733-12	2003	We therefore conclude that while pentostatin is a safe and active agent for T-NHL regardless of CD26 expression, it may selectively deplete CD26+ T lymphocytes, with potentially significant clinical implications.	Pentostatin	33-44	dipeptidyl peptidase 4	Homo sapiens	140-144
12771621-1	2003	OBJECTIVE: We sought to determine the potential usefulness of 2"-deoxycoformycin (pentostatin), an inhibitor of adenosine deaminase, as a postinsult, or prophylactic treatment for systemic inflammatory response syndrome resulting from fecal peritonitis.	Pentostatin	62-80	adenosine deaminase	Rattus norvegicus	112-131
12845481-9	2003	Since T-PLL is refractory to conventional therapies with a poor prognosis, an intensive chemotherapy such as 2"-deoxycoformycin with anti-CDw52 monoclonal antibodies is usually favored.	Pentostatin	109-127	CD52 molecule	Homo sapiens	138-143
12816884-4	2003	17beta-estradiol diminished angiotensin II-induced free radical production in vascular smooth muscle cells (DCF fluorescence laser microscopy).	Pentostatin	108-111	angiotensinogen	Homo sapiens	28-42
12771621-1	2003	OBJECTIVE: We sought to determine the potential usefulness of 2"-deoxycoformycin (pentostatin), an inhibitor of adenosine deaminase, as a postinsult, or prophylactic treatment for systemic inflammatory response syndrome resulting from fecal peritonitis.	Pentostatin	82-93	adenosine deaminase	Rattus norvegicus	112-131
12643924-1	2003	We searched for non-nucleoside inhibitors of adenosine deaminase by rational structure-based de novo design and succeeded in the discovery of 1-(1-hydroxy-4-phenyl-2-butyl)imidazole-4-carboxamide (FR221647: K(i)=5.9 microM to human ADA) as a novel inhibitor with moderate activity and good pharmacokinetics compared with the known inhibitors pentostatin and EHNA.	Pentostatin	342-353	adenosine deaminase	Homo sapiens	232-235
12670468-1	2003	Pentostatin (2"-deoxycoformycin; Nipent), a potent inhibitor of adenosine deaminase, is a purine nucleoside analogue that is highly effective in the treatment of hairy-cell leukemia.	Pentostatin	0-11	adenosine deaminase	Homo sapiens	64-83
12670468-1	2003	Pentostatin (2"-deoxycoformycin; Nipent), a potent inhibitor of adenosine deaminase, is a purine nucleoside analogue that is highly effective in the treatment of hairy-cell leukemia.	Pentostatin	13-31	adenosine deaminase	Homo sapiens	64-83
12670468-1	2003	Pentostatin (2"-deoxycoformycin; Nipent), a potent inhibitor of adenosine deaminase, is a purine nucleoside analogue that is highly effective in the treatment of hairy-cell leukemia.	Pentostatin	33-39	adenosine deaminase	Homo sapiens	64-83
12091165-2	2002	Pentostatin (2"-deoxycoformycin), an inhibitor of adenosine deaminase, was administered to mice immediately after induction of sepsis by cecal ligation and puncture.	Pentostatin	0-11	adenosine deaminase	Mus musculus	50-69
12091165-2	2002	Pentostatin (2"-deoxycoformycin), an inhibitor of adenosine deaminase, was administered to mice immediately after induction of sepsis by cecal ligation and puncture.	Pentostatin	13-31	adenosine deaminase	Mus musculus	50-69
12091165-7	2002	Circulating levels of interleukin-6, tumor necrosis factor-alpha, and soluble tumor necrosis factor type II receptor were decreased in septic mice treated with pentostatin.	Pentostatin	160-171	interleukin 6	Mus musculus	22-64
11906243-8	2002	Inhibitors of nitric oxide synthase and phospholipase A2 led to a significant reduction of the DCF fluorescence and cell death.	Pentostatin	95-98	phospholipase A2 group IB	Rattus norvegicus	40-56
12111871-0	2002	Cd8(+)/V beta 5.1(+) large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin.	Pentostatin	174-191	CD8a molecule	Homo sapiens	0-3
11959672-5	2002	PNT dose dependently attenuated, without ablating, the elevation in serum TNF-alpha and IL-1beta and raised liver and spleen IL-10.	Pentostatin	0-3	tumor necrosis factor	Rattus norvegicus	74-83
11959672-5	2002	PNT dose dependently attenuated, without ablating, the elevation in serum TNF-alpha and IL-1beta and raised liver and spleen IL-10.	Pentostatin	0-3	interleukin 1 beta	Rattus norvegicus	88-96
11959672-5	2002	PNT dose dependently attenuated, without ablating, the elevation in serum TNF-alpha and IL-1beta and raised liver and spleen IL-10.	Pentostatin	0-3	interleukin 10	Rattus norvegicus	125-130
12061204-1	2002	The high therapeutic efficiency of lymphotoxic purine analogues, pentostatin and cladribine in hairy cell leukaemia which express the antigen CD25 (alpha chain interleukin-2 receptor) suggests the hypothesis whether protracted cellular immunodeficiency after treatment does not represent an important mechanism of control of this specific lymphoproliferation.	Pentostatin	65-76	interleukin 2 receptor subunit alpha	Homo sapiens	142-146
11522446-8	2001	Pretreatment with 2"-deoxycoformycin (DCF), inhibitor of adenosine deaminase, abolished these effects of PAN on cultured GECs.	Pentostatin	18-36	adenosine deaminase	Homo sapiens	57-76
11978140-16	2002	At the forefront of systemic chemotherapy development, pegylated liposomal doxorubicin, gemcitabine, and pentostatin appear to have the greatest potential for success in CTCL therapy.	Pentostatin	105-116	TSPY like 2	Homo sapiens	170-174
12150791-6	2002	The A(1) receptor agonist-induced aggregation was blocked by R-deoxycoformycin, an irreversible adenosine deaminase inhibitor.	Pentostatin	61-78	adenosine deaminase	Homo sapiens	96-115
12150791-8	2002	R-Deoxycoformycin treatment, which has previously been shown to block the interaction between adenosine deaminase and A(1) receptors, and which is crucial for the high-affinity state of the A(1) receptor, also blocked the A(1) receptor agonist-induced loss of high-affinity D(1) receptor binding.	Pentostatin	0-17	adenosine deaminase	Homo sapiens	94-113
11522446-8	2001	Pretreatment with 2"-deoxycoformycin (DCF), inhibitor of adenosine deaminase, abolished these effects of PAN on cultured GECs.	Pentostatin	38-41	adenosine deaminase	Homo sapiens	57-76
11404490-1	2001	The purpose of this phase II trial was to evaluate the toxicity of a sequential chemoradiotherapy approach using docetaxel, cisplatin, and 5-fluorouracil (5-FU) (DCF) with granulocyte colony-stimulating factor support in previously untreated patients with locally advanced head and neck cancer (HNC).	Pentostatin	162-165	colony stimulating factor 3	Homo sapiens	172-209
10609556-3	2000	In the presence of dCF (2.5 microM), TdT+ leukemic cells (N = 5) were sensitive to the cytotoxic effect of 3"-dA, whereas TdT (N = 6) cells were not.	Pentostatin	19-22	DNA nucleotidylexotransferase	Homo sapiens	37-40
10942399-2	2000	However, previous studies have shown that in the presence of 2"-deoxyadenosine (dAd), human monocytoid leukemia cell lines are much more sensitive to dCF with regard to the inhibition of cell proliferation.	Pentostatin	150-153	Daughters against dpp	Drosophila melanogaster	80-83
10942399-3	2000	Thus, dCF might be useful for treating monocytoid leukemia with the aid of dAd analogs.	Pentostatin	6-9	Daughters against dpp	Drosophila melanogaster	75-78
10942399-5	2000	In the presence of 10 micromol/L dAd, the concentration of dCF required to inhibit the viability of primary monocytoid leukemia cells was much lower than that required to inhibit normal or non-monocytoid leukemic cells.	Pentostatin	59-62	Daughters against dpp	Drosophila melanogaster	33-36
10942399-6	2000	Among the dAd analogs, 9-beta-D-arabinofuranosyladenine (AraA) was also effective in combination with dCF.	Pentostatin	102-105	Daughters against dpp	Drosophila melanogaster	10-13
10930997-6	2000	Accordingly, the combination of dCF (10-100 microM) plus dAdo was able to induce a dose-dependent inhibition of clonogenic growth and [3H]-thymidine incorporation in purified CD3+/CD4-/CD8- gammadelta+ tumour cells.	Pentostatin	32-35	CD4 molecule	Homo sapiens	180-183
10930997-6	2000	Accordingly, the combination of dCF (10-100 microM) plus dAdo was able to induce a dose-dependent inhibition of clonogenic growth and [3H]-thymidine incorporation in purified CD3+/CD4-/CD8- gammadelta+ tumour cells.	Pentostatin	32-35	CD8a molecule	Homo sapiens	185-188
10820140-6	2000	The objectives of the study were to determine whether the ADA inhibitors 2"-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine were capable of achieving a substantial and selective inhibition of gut wall activation of 6AC, and to determine whether the systemic concentrations of 6AC would be thus increased.	Pentostatin	73-91	adenosine deaminase	Rattus norvegicus	58-61
10877044-2	2000	The components of CTCL are reviewed to provide a background for understanding the role of pentostatin (Nipent; SuperGen, San Ramon, CA) in CTCL.	Pentostatin	90-101	TSPY like 2	Homo sapiens	18-22
10877044-2	2000	The components of CTCL are reviewed to provide a background for understanding the role of pentostatin (Nipent; SuperGen, San Ramon, CA) in CTCL.	Pentostatin	90-101	TSPY like 2	Homo sapiens	139-143
10877044-2	2000	The components of CTCL are reviewed to provide a background for understanding the role of pentostatin (Nipent; SuperGen, San Ramon, CA) in CTCL.	Pentostatin	103-109	TSPY like 2	Homo sapiens	139-143
10877054-4	2000	Of 94 CTCL patients treated on five phase II studies with single-agent pentostatin, the overall response rate was 40%, with a 7% complete response rate; the median time to progression ranged from 1.3 to 8.3 months.	Pentostatin	71-82	TSPY like 2	Homo sapiens	6-10
10877054-7	2000	In summary, pentostatin has demonstrated impressive activity in patients with advanced and refractory CTCL.	Pentostatin	12-23	TSPY like 2	Homo sapiens	102-106
10877054-8	2000	Additional studies using pentostatin in earlier-stage CTCL or in combination with other active agents in advanced disease are warranted.	Pentostatin	25-36	TSPY like 2	Homo sapiens	54-58
10839200-3	2000	Time dependent increases in DCF-fluorescence as a measure of reactive oxygen load were quantified in single cells after incubation with TNF-alpha, IL-1 and IFN-gamma.	Pentostatin	28-31	tumor necrosis factor	Mus musculus	136-145
10839200-3	2000	Time dependent increases in DCF-fluorescence as a measure of reactive oxygen load were quantified in single cells after incubation with TNF-alpha, IL-1 and IFN-gamma.	Pentostatin	28-31	interleukin 1 complex	Mus musculus	147-151
10839200-3	2000	Time dependent increases in DCF-fluorescence as a measure of reactive oxygen load were quantified in single cells after incubation with TNF-alpha, IL-1 and IFN-gamma.	Pentostatin	28-31	interferon gamma	Mus musculus	156-165
11226375-6	2001	2"-Deoxycoformycin, an inhibitor of adenosine deaminase, enhanced caspase activation by adenosine but had no effect by itself.	Pentostatin	0-18	adenosine deaminase	Mus musculus	36-55
11067867-2	2000	C57BL/6 fetal thymuses treated with the specific ADA inhibitor 2"-deoxycoformycin exhibited features of the human disease, including accumulation of dATP and inhibition of S-adenosylhomocysteine hydrolase enzyme activity.	Pentostatin	63-81	adenosine deaminase	Homo sapiens	49-52
10926348-3	2000	Cytarabine is principally active in the S phase of the cell cycle and is most toxic to replicating cells, whereas pentostatin, fludarabine and cladribine are incorporated into DNA during the process in which strand breaks are repaired and are therefore cytotoxic to slowly replicating cells (although the action of pentostatin results from its inhibition of adenosine deaminase).	Pentostatin	114-125	adenosine deaminase	Homo sapiens	358-377
10887640-5	2000	This trial will evaluate the effect of pentostatin (Nipent), a potent adenosine deaminase inhibitor with known efficacy against T-cell malignancies, on relapsed/refractory T-cell lymphomas in relation to CD26 expression.	Pentostatin	39-50	adenosine deaminase	Homo sapiens	70-89
10887640-5	2000	This trial will evaluate the effect of pentostatin (Nipent), a potent adenosine deaminase inhibitor with known efficacy against T-cell malignancies, on relapsed/refractory T-cell lymphomas in relation to CD26 expression.	Pentostatin	39-50	dipeptidyl peptidase 4	Homo sapiens	204-208
10887640-5	2000	This trial will evaluate the effect of pentostatin (Nipent), a potent adenosine deaminase inhibitor with known efficacy against T-cell malignancies, on relapsed/refractory T-cell lymphomas in relation to CD26 expression.	Pentostatin	52-58	adenosine deaminase	Homo sapiens	70-89
9622483-2	1998	The X-ray structures of murine adenosine deaminase with bound potent inhibitors (Ki values approximately 10(-13) M) (8R)-hydroxyl-2"-deoxycoformycin (pentostatin), a transition state analogue, and (6S)-hydroxyl-1,6-dihydropurine riboside, a reaction coordinate analogue, have been determined and refined to resolutions of 2.6 and 1.95 A, respectively.	Pentostatin	150-161	adenosine deaminase	Mus musculus	31-50
10488704-4	1999	METHODS: Whole blood from 17 patients and 17 healthy controls stimulated with lipopolysaccharide was cultured in the presence of adenosine at different concentrations and, in some experiments, with the adenosine deaminase inhibitor deoxycoformycin.	Pentostatin	232-247	adenosine deaminase	Homo sapiens	202-221
10488704-8	1999	To test the hypothesis that plasma adenosine deaminase, which was increased in the patients" plasma, was actually involved in this blunted response to adenosine in alcoholic cirrhosis, we performed adenosine dose-response experiments and pharmacologically blocked adenosine deaminase activity with deoxycoformycin.	Pentostatin	298-313	adenosine deaminase	Homo sapiens	35-54
10529513-1	1999	Following the administration of the human anti-CD20 monoclonal antibody IDEC-C2B8 (rituximab), a 31-year-old woman with B-prolymphocytic leukemia, who had been resistant to CHOP, fludarabine, pentostatin and 2-CdA, achieved complete remission.	Pentostatin	192-203	keratin 20	Homo sapiens	47-51
9787175-0	1998	Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2"-deoxycoformycin and 2"-deoxyadenosine: association with dATP-dependent activation of caspase-3.	Pentostatin	77-95	caspase 3	Homo sapiens	165-174
9787175-8	1998	Induction of caspase-3 (CPP32) activity accompanied the apoptosis induced by dCF plus dAd.	Pentostatin	77-80	caspase 3	Homo sapiens	13-22
9787175-8	1998	Induction of caspase-3 (CPP32) activity accompanied the apoptosis induced by dCF plus dAd.	Pentostatin	77-80	caspase 3	Homo sapiens	24-29
10440915-1	1999	We present a case of a patient who developed all manifestations of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) acutely following treatment of cutaneous T-cell lymphoma (CTCL, Sezary syndrome) with deoxycoformycin (pentostatin).	Pentostatin	225-240	TSPY like 2	Homo sapiens	197-201
10440915-1	1999	We present a case of a patient who developed all manifestations of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) acutely following treatment of cutaneous T-cell lymphoma (CTCL, Sezary syndrome) with deoxycoformycin (pentostatin).	Pentostatin	242-253	TSPY like 2	Homo sapiens	197-201
9726984-5	1998	2"-Deoxycoformycin, an adenosine deaminase (EC 3.5.4.4) inhibitor, increased the potency of adenosine 5-fold, suggesting that the effectiveness of adenosine as an autophagy inhibitor was curtailed by its intracellular deamination.	Pentostatin	0-18	adenosine deaminase	Rattus norvegicus	23-42
9572907-8	1998	Co-perfusion of the potent, hydrophilic ADA inhibitor DCF (Ki = 0.	Pentostatin	54-57	adenosine deaminase	Rattus norvegicus	40-43
9399998-12	1997	Also, their potential for immunotoxicity, if any, appears to be transient in nature, representing an important clinical advantage compared with tight-binding ADA inhibitors such as deoxycoformycin.	Pentostatin	181-196	adenosine deaminase	Rattus norvegicus	158-161
9495239-1	1998	We have assessed the intracellular metabolism of 2"-deoxyadenosine in a human colon-carcinoma cell line (LoVo), both in the absence and in the presence of deoxycoformycin, the powerful inhibitor of adenosine deaminase.	Pentostatin	155-170	adenosine deaminase	Homo sapiens	198-217
9342431-10	1997	Pentostatin also resulted in a significant reduction in the accumulation of inosine and hypoxanthine, indicating inhibition of adenosine deaminase activity.	Pentostatin	0-11	adenosine deaminase	Homo sapiens	127-146
9178835-2	1997	Recently, the high activity of nucleoside analogs as fludarabine (FAMP), 2-chlorodeoxyadenosine (2-CDA) and 2-deoxycoformycin (DCF) in low-grade NHLs has caused a new reawakening interest in CLL concerning new treatment strategies, the biology and prognostic factors of this disease.	Pentostatin	127-130	cytidine deaminase	Homo sapiens	99-102
9210198-9	1997	DCF pre-treatment inhibited brain tissue ADA, abolishing the prodrug effect, and enhancing F-ddA concentrations in both brain parenchyma (5x) and CSF (6x).	Pentostatin	0-3	adenosine deaminase	Rattus norvegicus	41-44
9204061-2	1997	Pentostatin is a potent inhibitor of adenosine deaminase and is selectively toxic to lymphocytes.	Pentostatin	0-11	adenosine deaminase	Homo sapiens	37-56
9204061-4	1997	OBJECTIVE: Our purpose was to evaluate the efficacy and safety of pentostatin in the treatment of patients with advanced and/or therapy-refractory CTCL.	Pentostatin	66-77	TSPY like 2	Homo sapiens	147-151
9204061-11	1997	CONCLUSION: Single-agent pentostatin in intravenous doses of 4 to 5 mg/m2 is an effective systemic treatment of CTCL (39% objective response rate) with little toxicity.	Pentostatin	25-36	TSPY like 2	Homo sapiens	112-116
9087581-5	1997	Pretreatment with the adenosine uptake blocker dipyridamole or the adenosine deaminase inhibitor deoxycoformycin enhanced the adenosine action, and this enhancement was not observed in the endothelium-denuded tissues.	Pentostatin	97-112	adenosine deaminase	Canis lupus familiaris	67-86
9013123-1	1997	Puromycin aminonucleoside (PAN) toxicity was totally inhibited in the rat in vivo and in cultured glomerular epithelial cells (GECs) in vitro using the adenosine deaminase (ADA) inhibitor, 2"-deoxycoformycin (DCF).	Pentostatin	189-207	adenosine deaminase	Rattus norvegicus	173-176
9045870-5	1997	Thymic adenosine concentrations of mice treated with the ADA inhibitor 2"-deoxycoformycin (dCF) were elevated over 30-fold, suggesting that high ADA activity, rather than an absence of 5"-NT, is mainly responsible for low thymic adenosine levels.	Pentostatin	71-89	adenosine deaminase	Mus musculus	57-60
9045870-5	1997	Thymic adenosine concentrations of mice treated with the ADA inhibitor 2"-deoxycoformycin (dCF) were elevated over 30-fold, suggesting that high ADA activity, rather than an absence of 5"-NT, is mainly responsible for low thymic adenosine levels.	Pentostatin	71-89	adenosine deaminase	Mus musculus	145-148
9045870-5	1997	Thymic adenosine concentrations of mice treated with the ADA inhibitor 2"-deoxycoformycin (dCF) were elevated over 30-fold, suggesting that high ADA activity, rather than an absence of 5"-NT, is mainly responsible for low thymic adenosine levels.	Pentostatin	91-94	adenosine deaminase	Mus musculus	57-60
9045870-5	1997	Thymic adenosine concentrations of mice treated with the ADA inhibitor 2"-deoxycoformycin (dCF) were elevated over 30-fold, suggesting that high ADA activity, rather than an absence of 5"-NT, is mainly responsible for low thymic adenosine levels.	Pentostatin	91-94	adenosine deaminase	Mus musculus	145-148
9045870-6	1997	The adenosine concentrations in dCF-treated mice are sufficient to cause adenosine receptor-mediated thymocyte apoptosis in vitro, suggesting that adenosine accumulation could play a role in ADA-deficient severe combined immunodeficiency.	Pentostatin	32-35	adenosine deaminase	Mus musculus	191-194
9013123-1	1997	Puromycin aminonucleoside (PAN) toxicity was totally inhibited in the rat in vivo and in cultured glomerular epithelial cells (GECs) in vitro using the adenosine deaminase (ADA) inhibitor, 2"-deoxycoformycin (DCF).	Pentostatin	209-212	adenosine deaminase	Rattus norvegicus	173-176
9013123-2	1997	DCF completely inhibited ADA activity in glomeruli and protected against the development of PAN nephrosis; the 24-h urinary protein excretion of treated rats compared with controls (PAN rats) 9 days after PAN injection was 16 +/- 2 mg and 524 +/- 55 mg, respectively (p &lt; .01).	Pentostatin	0-3	adenosine deaminase	Rattus norvegicus	25-28
8846128-3	1996	2"-deoxycoformycin (2"-dCF) is an inhibitor of adenosine deaminase (ADA) and is toxic to lymphocytes and monocytes.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	47-66
9001417-1	1997	The long-term outcome of patients with hairy cell leukemia resistant to interferon-alpha (IFN-alpha) following treatment with deoxycoformycin (DCF) was examined, and the kinetics of recovery of lymphocyte subsets and factors influencing the rate of recovery investigated.	Pentostatin	126-141	interferon alpha 1	Homo sapiens	90-99
9001417-8	1997	After DCF, nadir CD4+ and CD8+ lymphocyte counts were significantly lower than prior to therapy (P &lt; 0.0001 and P = 0.05, respectively), but returned to baseline levels during follow-up.	Pentostatin	6-9	CD4 molecule	Homo sapiens	17-20
9001417-8	1997	After DCF, nadir CD4+ and CD8+ lymphocyte counts were significantly lower than prior to therapy (P &lt; 0.0001 and P = 0.05, respectively), but returned to baseline levels during follow-up.	Pentostatin	6-9	CD8a molecule	Homo sapiens	26-29
8986139-0	1996	Effect of deoxycoformycin and Val-boroPro on the associated catalytic activities of lymphocyte CD26 and ecto-adenosine deaminase.	Pentostatin	10-25	dipeptidyl peptidase 4	Homo sapiens	95-99
9022297-1	1996	Human lymphocytes lacking adenosine deaminase die and T-cell leukemias are killed by deoxycoformycin (dCf), an inhibitor of adenosine deaminase, due to impaired metabolism of dAdo.	Pentostatin	85-100	adenosine deaminase	Homo sapiens	124-143
9022297-1	1996	Human lymphocytes lacking adenosine deaminase die and T-cell leukemias are killed by deoxycoformycin (dCf), an inhibitor of adenosine deaminase, due to impaired metabolism of dAdo.	Pentostatin	102-105	adenosine deaminase	Homo sapiens	26-45
9022297-1	1996	Human lymphocytes lacking adenosine deaminase die and T-cell leukemias are killed by deoxycoformycin (dCf), an inhibitor of adenosine deaminase, due to impaired metabolism of dAdo.	Pentostatin	102-105	adenosine deaminase	Homo sapiens	124-143
8846128-3	1996	2"-deoxycoformycin (2"-dCF) is an inhibitor of adenosine deaminase (ADA) and is toxic to lymphocytes and monocytes.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	68-71
8846128-3	1996	2"-deoxycoformycin (2"-dCF) is an inhibitor of adenosine deaminase (ADA) and is toxic to lymphocytes and monocytes.	Pentostatin	20-26	adenosine deaminase	Homo sapiens	47-66
8846128-3	1996	2"-deoxycoformycin (2"-dCF) is an inhibitor of adenosine deaminase (ADA) and is toxic to lymphocytes and monocytes.	Pentostatin	20-26	adenosine deaminase	Homo sapiens	68-71
14651224-5	1996	It was anticipated that pentostatin would be most active in neoplasms with high intracellular concentrations of ADA, e.g. acute lymphocytic leukemia (ALL), particularly of the T-cell variety.	Pentostatin	24-35	adenosine deaminase	Homo sapiens	112-115
8779915-5	1996	Inhibition of endogenous adenosine deaminase activity by erythro-9-(2-hydroxy-3-nonyl)adenine or 2"-deoxycoformycin strongly enhanced the inhibitory effects of exogenous adenosine on cytokine release and expression of E-selectin and VCAM-1.	Pentostatin	97-115	selectin E	Homo sapiens	218-228
8779915-5	1996	Inhibition of endogenous adenosine deaminase activity by erythro-9-(2-hydroxy-3-nonyl)adenine or 2"-deoxycoformycin strongly enhanced the inhibitory effects of exogenous adenosine on cytokine release and expression of E-selectin and VCAM-1.	Pentostatin	97-115	vascular cell adhesion molecule 1	Homo sapiens	233-239
9010576-1	1996	The observation of lymphopenia in children deficient in adenosine deaminase (ADA) led to exploration of an inhibitor of the enzyme in lymphoid malignancies; thus deoxycoformycin was the first purine nucleotide used in human trials.	Pentostatin	162-177	adenosine deaminase	Homo sapiens	56-75
9010576-1	1996	The observation of lymphopenia in children deficient in adenosine deaminase (ADA) led to exploration of an inhibitor of the enzyme in lymphoid malignancies; thus deoxycoformycin was the first purine nucleotide used in human trials.	Pentostatin	162-177	adenosine deaminase	Homo sapiens	77-80
14651224-7	1996	By contrast, pentostatin proved to be exceptionally active in hairy cell leukemia (HCL), a B-cell neoplasm with low intracellular concentrations of ADA.	Pentostatin	13-24	adenosine deaminase	Homo sapiens	148-151
8846098-3	1995	An inhibitor of adenosine deaminase (deoxycoformycin, DCF) in combination with an inhibitor of adenosine transport (dilazep, DLZP) at a dose that did not affect levels of endogenous adenosine, potentiated NMDA-induced increases in adenosine levels to 426% of contralateral striata.	Pentostatin	37-52	adenosine deaminase	Rattus norvegicus	16-35
19927594-6	1996	This is the first report of deoxycoformycin phosphorylation catalyzed by a 5"-nucleotidase purified from eukaryotic cells.	Pentostatin	28-43	5'-nucleotidase ecto	Homo sapiens	75-90
8683870-11	1996	Our results suggest that DCF is beneficial for chemotherapy-resistant generalized erythroderma in CTCL.	Pentostatin	25-28	TSPY like 2	Homo sapiens	98-102
7622293-4	1995	The phosphorylation of dAdo by adenosine kinase appears to play a central role in the toxicity of the deoxynucleoside in combination with dCF.	Pentostatin	138-141	adenosine kinase	Homo sapiens	31-47
7489256-4	1995	The Krebs-Henseleit solution contained 5"-iodotubercidin and 2"-deoxycoformycin, which inhibit adenosine kinase and adenosine deaminase, respectively.	Pentostatin	61-79	adenosine kinase	Canis lupus familiaris	95-111
7489256-4	1995	The Krebs-Henseleit solution contained 5"-iodotubercidin and 2"-deoxycoformycin, which inhibit adenosine kinase and adenosine deaminase, respectively.	Pentostatin	61-79	adenosine deaminase	Canis lupus familiaris	116-135
8590388-6	1995	In contrast with reports on 2"-deoxycoformycin (Cooney et al., 1987), the adenosine deaminase inhibitors tested by us showed a significant increase in the antiviral activity of ddAdo, but not of ddIno.	Pentostatin	28-46	adenosine deaminase	Homo sapiens	74-93
7622293-6	1995	Moreover, the cytotoxic effect was almost completely reversed in the 3 cell lines when inhibitors of adenosine kinase, such as 5"-amino-5"-deoxyadenosine and iodotubercidine, were added to the culture medium together with dCF and dAdo.	Pentostatin	222-225	adenosine kinase	Homo sapiens	101-117
7606748-1	1995	OBJECTIVE: The objectives were to determine the effects of the adenosine deaminase inhibitor pentostatin (deoxycoformycin) on interstitial fluid (ISF) adenosine before, during, and after myocardial ischaemia and to ascertain whether augmented endogenous ISF adenosine reduces myocardial infarction.	Pentostatin	93-104	adenosine deaminase	Canis lupus familiaris	63-82
7606748-1	1995	OBJECTIVE: The objectives were to determine the effects of the adenosine deaminase inhibitor pentostatin (deoxycoformycin) on interstitial fluid (ISF) adenosine before, during, and after myocardial ischaemia and to ascertain whether augmented endogenous ISF adenosine reduces myocardial infarction.	Pentostatin	106-121	adenosine deaminase	Canis lupus familiaris	63-82
7640871-2	1995	2"-Deoxycoformycin (Pentostatin, DCF) irreversibly inhibits ADA and therefore has been suggested as an immunosuppressive drug.	Pentostatin	0-18	adenosine deaminase	Rattus norvegicus	60-63
7640871-2	1995	2"-Deoxycoformycin (Pentostatin, DCF) irreversibly inhibits ADA and therefore has been suggested as an immunosuppressive drug.	Pentostatin	20-31	adenosine deaminase	Rattus norvegicus	60-63
7640871-2	1995	2"-Deoxycoformycin (Pentostatin, DCF) irreversibly inhibits ADA and therefore has been suggested as an immunosuppressive drug.	Pentostatin	33-36	adenosine deaminase	Rattus norvegicus	60-63
7733907-0	1995	Mutagenesis of human adenosine deaminase to active forms that partially resist inhibition by pentostatin.	Pentostatin	93-104	adenosine deaminase	Homo sapiens	21-40
7733907-1	1995	Human adenosine deaminase (ADA) cDNA was randomly mutagenized in vitro and bacterial transformants were selected for resistance to the potent enzyme inhibitor, pentostatin (dCF).	Pentostatin	160-171	adenosine deaminase	Homo sapiens	6-25
7733907-1	1995	Human adenosine deaminase (ADA) cDNA was randomly mutagenized in vitro and bacterial transformants were selected for resistance to the potent enzyme inhibitor, pentostatin (dCF).	Pentostatin	160-171	adenosine deaminase	Homo sapiens	27-30
7733907-1	1995	Human adenosine deaminase (ADA) cDNA was randomly mutagenized in vitro and bacterial transformants were selected for resistance to the potent enzyme inhibitor, pentostatin (dCF).	Pentostatin	173-176	adenosine deaminase	Homo sapiens	6-25
7733907-1	1995	Human adenosine deaminase (ADA) cDNA was randomly mutagenized in vitro and bacterial transformants were selected for resistance to the potent enzyme inhibitor, pentostatin (dCF).	Pentostatin	173-176	adenosine deaminase	Homo sapiens	27-30
7733907-2	1995	Cells transformed with mutant plasmids dCF-R2 and dCF-R6 were able to grow in the presence of 10(-6) M dCF, whereas 10(-11) M dCF blocked growth of cells complemented with wild-type ADA.	Pentostatin	39-42	adenosine deaminase	Homo sapiens	182-185
7733907-2	1995	Cells transformed with mutant plasmids dCF-R2 and dCF-R6 were able to grow in the presence of 10(-6) M dCF, whereas 10(-11) M dCF blocked growth of cells complemented with wild-type ADA.	Pentostatin	50-53	adenosine deaminase	Homo sapiens	182-185
7646420-0	1995	Effect of adenosine deaminase inhibition with pentostatin on myocardial stunning in dogs.	Pentostatin	46-57	adenosine deaminase	Canis lupus familiaris	10-29
11847552-5	1995	It was anticipated that pentostatin would be most active in neoplasms with high intracellular concentrations of ADA---e.g., acute lymphocytic leukemia (ALL), particularly its T cell variety.	Pentostatin	24-35	adenosine deaminase	Homo sapiens	112-115
11847552-7	1995	By contrast, pentostatin proved to be exceptionally active in hairy cell leukemia (HCL), a B cell neoplasm with low intracellular concentrations of ADA.	Pentostatin	13-24	adenosine deaminase	Homo sapiens	148-151
7646420-1	1995	Pentostatin (2-deoxycoformycin) is a potent inhibitor of adenosine deaminase and has been demonstrated to augment endogenous adenosine levels during regional and global myocardial ischemia.	Pentostatin	0-11	adenosine deaminase	Canis lupus familiaris	57-76
7646420-1	1995	Pentostatin (2-deoxycoformycin) is a potent inhibitor of adenosine deaminase and has been demonstrated to augment endogenous adenosine levels during regional and global myocardial ischemia.	Pentostatin	13-30	adenosine deaminase	Canis lupus familiaris	57-76
7646420-2	1995	Based on the rationale that increasing endogenous adenosine during ischemia may be cardioprotective, the objective of this study was to determine if adenosine deaminase inhibition with pentostatin could improve postischemic contractile dysfunction (stunning) in open-chest anesthetized dogs.	Pentostatin	185-196	adenosine deaminase	Canis lupus familiaris	149-168
7891860-5	1994	The effects of adenosine deaminase were prevented by the specific inhibitor, deoxycoformycin (30 microM).	Pentostatin	77-92	adenosine deaminase	Rattus norvegicus	15-34
17180017-6	1995	Bcl 2 overproduction also suppressed the accumulation of dAMP, dADP and dATP in cells exposed to 2"-deoxyadenosine in the presence of pentostatin to abrogate the pronounced inversion of ATP/dATP pools associated with 2"-deoxyadenosine exposure.	Pentostatin	134-145	BCL2 apoptosis regulator	Homo sapiens	0-5
7669942-5	1995	Inhibition of the adenosine deaminase by deoxycoformycin permits a 6-fold increase in intracellular adenosine concentration relative to the medium by the Na(+)-dependent process.	Pentostatin	41-56	adenosine deaminase	Mus musculus	18-37
7669942-6	1995	Rapid inhibition of adenosine deaminase by deoxycoformycin occurs even in the presence of dipyridamole which prevents the entry of deoxycoformycin as well as adenosine into the cells in a Na(+)-free medium.	Pentostatin	43-58	adenosine deaminase	Mus musculus	20-39
7669942-6	1995	Rapid inhibition of adenosine deaminase by deoxycoformycin occurs even in the presence of dipyridamole which prevents the entry of deoxycoformycin as well as adenosine into the cells in a Na(+)-free medium.	Pentostatin	131-146	adenosine deaminase	Mus musculus	20-39
7969062-6	1994	This decrease in ddAdo and 2"-beta-F-ddAdo phosphorylation with higher levels of the inhibitor appears to result from intracellular penetration of 2"-dCF and consequent inhibition of intracellular deamination, a critical step in the activation of both agents through the 5"-nucleotidase pathway.	Pentostatin	147-153	5'-nucleotidase ecto	Homo sapiens	271-286
7525186-6	1994	The purine analogues fludarabine and cladribine (2-chloro-2"-deoxyadenosine) and the adenosine deaminase inhibitor deoxycoformycin all have therapeutic effects in a range of lymphoproliferative disorders.	Pentostatin	115-130	adenosine deaminase	Homo sapiens	85-104
7912015-6	1994	Consequently, 2-CdA is expected soon to displace both interferon alpha and deoxycoformycin as first line therapy in hairy cell leukemia.	Pentostatin	75-90	cytidine deaminase	Homo sapiens	16-19
7820042-3	1994	In this paper, we report our experience with dCF in a series of 38 HCL patients who had progression of their disease after IFN therapy.	Pentostatin	45-48	interferon alpha 1	Homo sapiens	123-126
7506651-2	1993	Pentostatin, a potent inhibitor of adenosine deaminase, is an antineoplastic agent which has been studied in the treatment of a variety of lymphoproliferative disorders.	Pentostatin	0-11	adenosine deaminase	Homo sapiens	35-54
8249784-3	1993	We determined whether 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase, could mimic the effect of preconditioning in nonpreconditioned rats and potentiate the salutary effect of preconditioning in preconditioned rats.	Pentostatin	22-40	adenosine deaminase	Rattus norvegicus	70-89
8249784-3	1993	We determined whether 2"-deoxycoformycin (DCF), a potent inhibitor of adenosine deaminase, could mimic the effect of preconditioning in nonpreconditioned rats and potentiate the salutary effect of preconditioning in preconditioned rats.	Pentostatin	42-45	adenosine deaminase	Rattus norvegicus	70-89
7685243-6	1993	Recently, the nucleosides pentostatin (2"-deoxycoformycin) (DCF) and 2"-chlorodeoxyadenosine (2-CdA) have been shown to produce greater numbers of durable complete remissions with curative potential in patients with HCL.	Pentostatin	60-63	cytidine deaminase	Homo sapiens	96-99
8338781-3	1993	Within the PBL subsets, major changes concerned the CD4+ T cells, which during DCF therapy were distinctly suppressed to nadir values of 0.038-0.18 (median 0.126) x 10(9)/l.	Pentostatin	79-82	CD4 molecule	Homo sapiens	52-55
8408919-3	1993	Elevated adenosine deaminase activity in T cell leukemia has been reported, and its inhibitor, deoxycoformycin, has been developed as an antitumor agent.	Pentostatin	95-110	adenosine deaminase	Homo sapiens	9-28
1279327-2	1992	Splenectomy as first line therapy has few indications; recombinant alfa interferon (IFN) leads to a high overall response rate but there are few bone marrow remissions; deoxycoformycin (dCF) or pentostatin leads to a higher complete bone marrow response rate than with IFN but follow-up biopsies show persistence of hairy cells; 2-chlorodeoxyadenosine (2-CdA) is a purine analog that after a single seven day intravenous infusion leads to a complete response rate.	Pentostatin	169-184	cytidine deaminase	Homo sapiens	355-358
8384443-9	1993	Adenosine production, measured in hepatocytes in which adenosine kinase and adenosine deaminase were inhibited by 5-iodotubercidin and deoxycoformycin respectively, was about 18 nmol/min per g of cells in normoxia; it increased about 2-fold in anoxia, although AMP increased 8-16-fold in this condition.	Pentostatin	135-150	adenosine kinase	Homo sapiens	55-71
8469375-1	1993	We determined whether 2"-deoxycoformycin (DCF), a potent highly specific inhibitor of adenosine deaminase (ADA), protected against transient forebrain ischemic neuronal injury in rat.	Pentostatin	22-40	adenosine deaminase	Rattus norvegicus	86-105
8469375-1	1993	We determined whether 2"-deoxycoformycin (DCF), a potent highly specific inhibitor of adenosine deaminase (ADA), protected against transient forebrain ischemic neuronal injury in rat.	Pentostatin	22-40	adenosine deaminase	Rattus norvegicus	107-110
8469375-1	1993	We determined whether 2"-deoxycoformycin (DCF), a potent highly specific inhibitor of adenosine deaminase (ADA), protected against transient forebrain ischemic neuronal injury in rat.	Pentostatin	42-45	adenosine deaminase	Rattus norvegicus	86-105
8469375-1	1993	We determined whether 2"-deoxycoformycin (DCF), a potent highly specific inhibitor of adenosine deaminase (ADA), protected against transient forebrain ischemic neuronal injury in rat.	Pentostatin	42-45	adenosine deaminase	Rattus norvegicus	107-110
8273368-4	1993	Other combinations of IFN-alpha with standard therapies and/or experimental therapies (Pentostatin) seem to contribute-according to preliminary data-to an improvement of remission rates in CTCL.	Pentostatin	87-98	interferon alpha 1	Homo sapiens	22-31
8273368-4	1993	Other combinations of IFN-alpha with standard therapies and/or experimental therapies (Pentostatin) seem to contribute-according to preliminary data-to an improvement of remission rates in CTCL.	Pentostatin	87-98	TSPY like 2	Homo sapiens	189-193
1449110-3	1992	2"-Deoxycoformycin is an inhibitor of adenosine deaminase (ADA), an enzyme found in relatively high amounts in malignant lymphoid cells.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	38-57
1449110-3	1992	2"-Deoxycoformycin is an inhibitor of adenosine deaminase (ADA), an enzyme found in relatively high amounts in malignant lymphoid cells.	Pentostatin	0-18	adenosine deaminase	Homo sapiens	59-62
1504093-1	1992	Several adenosine analogs, such as coformycin, 2"-deoxycoformycin and erythro-9-(3-nonyl-p-aminobenzyl)adenine (EHNA), which are strong inhibitors of mammalian adenosine deaminase, are much weaker inhibitors of the Saccharomyces cerevisiae enzyme.	Pentostatin	47-65	adenosine deaminase	Homo sapiens	160-179
1490883-1	1992	A practical process is described for the large-scale isolation of pentostatin, an adenosine deaminase inhibitor used clinically for the treatment of interferon-refractory hairy cell leukemia.	Pentostatin	66-77	adenosine deaminase	Homo sapiens	82-101